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HistopathologyThe applicability of rat precision-cut lung slices (PCLuS) in detecting nanomaterial (NM) toxicity to the respiratory
tract was investigated evaluating sixteen OECD reference NMs (TiO2, ZnO, CeO2, SiO2, Ag, multi-walled carbon
nanotubes (MWCNTs)). Upon 24-hour test substance exposure, the PCLuS system was able to detect early
events of NM toxicity: total protein, reduction in mitochondrial activity, caspase-3/-7 activation, glutathione
depletion/increase, cytokine induction, and histopathological evaluation. Ion shedding NMS (ZnO and Ag) induced
severe tissue destruction detected by the loss of total protein. Two anatase TiO2 NMs, CeO2 NMs, and twoMWCNT
caused signiﬁcant (determined by trend analysis) cytotoxicity in theWST-1 assay. At non-cytotoxic concentrations,
different TiO2 NMs and one MWCNT increased GSH levels, presumably a defense response to reactive oxygen
species, and these substances further induced a variety of cytokines. One of the SiO2 NMs increased caspase-3/-7
activities at non-cytotoxic levels, and one rutile TiO2 only induced cytokines. Investigating these effects is, however,
not sufﬁcient to predict apical effects found in vivo. Reproducibility of test substance measurements was not fully
satisfactory, especially in the GSH and cytokine assays. Effects were frequently observed in negative controls
pointing to tissue slice vulnerability even thoughprepared andhandledwithutmost care. Comparisons of the effects
observed in the PCLuS to in vivo effects reveal some concordances for the metal oxide NMs, but less so for the
MWCNT. The highest effective dosages, however, exceeded those reported for rat short-term inhalation studies.
To become applicable for NM testing, the PCLuS system requires test protocol optimization.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
In parallel to the emergence of nanotechnology as an innovative
enabling technology, many projects and studies on potential impacts
of nanomaterials (NMs) on human health and the environment
have advanced. NMs have been deﬁned as “natural, incidental or
manufactured material[s] containing particles, in an unbound state or
as an aggregate or as an agglomerate and where, for 50% or more of
the particles in the number size distribution, one or more external
dimensions is in the size range 1 nm–100 nm” (Anon, 2011). Theand Ecology, BASF SE, 67056
edel).
. Open access under CC BY license.OECD's Working Party on Manufactured Nanomaterials (WPMN) has
launched a Sponsorship Programme for the Testing of Manufactured
Nanomaterials to fund, coordinate, and conduct tests to establish
which kind of information on intrinsic properties may be relevant for
assessing the exposure and hazard of manufactured nanomaterials
(OECD, 2008, 2010). One aim of the WPMN is to collect relevant data
for the safety assessment of a representative set of NMs and to establish
the role of alternative methods to animal testing in nanotoxicology
(OECD, 2008).
As regards exposure to NMs, inhalation is recognized as amain route
of uptake, especially in the occupational context, but also for consumers
(Aitken et al., 2011; Klein et al., 2012). TheWPMNhas proposed a short-
term rat inhalation study (STIS) as a suitable reduction and reﬁnement
alternative to obtain information on early key elements of pathogenesis,
as well as on the persistence, progression and/or regression of effects,
while also addressing organ burden in the lung and potential transloca-
tion to other tissues (Klein et al., 2012). Additionally, intratracheal
instillation studies have been applied for NM testing. However, the
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tion has been questioned (Landsiedel et al., 2012). Although animal
numbers and exposure durations are reduced in these two in vivo
methods as compared to the acute inhalation toxicity study described
in OECD Test Guideline 403 (OECD, 2009), they both still require the
use and euthanasia of animals.
A replacement method to determine nanomaterial short-term
inhalation toxicity remains to be developed. Nanomaterials have been
applied in a vast amount of different cell culture systems consisting of
one or more cell types — of pulmonary or other origin, using human
or animal primary cells or cell lines, and a variety of different endpoint
detection methods (Hackenberg et al., 2011; Kroll et al., 2011; Stone
et al., 2009). Cells have been cultured in suspension or at the air–liquid
interface (Rothen-Rutishauser et al., 2005). The results obtained in such
in vitro testmethodshave not been consistent, and standardized in vitro
test methods to determine early cellular effects upon NM exposure
remain to be developed (Gasser et al., 2012; Nel et al., 2013a,b).
Consequently, the relevance of in vitro test results in predicting NM
effects in vivo is a matter of controversy, not least because cell culture
systems lack the structural identity of the pulmonary tissue (Hirsch
et al., 2011; Nel et al., 2013a).
Against this background it was the goal of the current study to
investigate the applicability of rat precision-cut lung slices (PCLuS) as
an ex vivo test method to determine the respiratory effects of NMs.
Whereas a pre-validation study investigating the suitability of PCLuS
in predicting short-term respiratory toxicity of conventional, non-
nanoform chemicals, funded by the German Federal Ministry for
Education and Research, is currently under way (Lauenstein et al.,
2012), their applicability for the testing of NMs has not yet been
evaluated systematically.
PCLuS, typically cut to a thickness of approximately 200–300 μm,
contain all the cell types present in the lung including those relevant
for inducing immune responses, i.e. dendritic cells, macrophages,
and mast cells (Henjakovic et al., 2008). Pulmonary morphology
and organ-typical cell–cell structures enabling intercellular commu-
nication are maintained for up to 70 h (BéruBé et al., 2009; Martin
et al., 1996). Thereby reﬂecting physiological pulmonary histology,
the ex vivo PCLuS system has already been used to study a variety
of scientiﬁc problems relating to the lung, ranging from pharmaco-
logical effects on the airway system (Martin et al., 1996), pulmonary
function (Martin et al., 2000), and toxicological effects of bulk or
nanoscale substances (Nassimi et al., 2009). Results from PCLuS
studies have been evaluated to be precise and reproducible
(Martin et al., 1996). However, also the contrary has been reported:
BéruBé et al. (2009) warned against possibly large variations in the
results obtained with replicate slices and with slices from different
donors.
The test substances applied were the 16 NMs available at the onset
of the present study in the repository of representative nanomaterials
that the European Commission's Joint Research Centre (JRC) has
established in support of the OECD WPMN's Sponsorship Programme
(Singh et al., 2011; see also: http://ihcp.jrc.ec.europa.eu/our_activities/
nanotechnology/nanomaterials-repository/list_materials_JRC_rep_oct_
2011.pdf/view. Note: All websites were accessed in November 2013.)
The NMs comprised anatase, rutile, and rutile-anatase titanium dioxide
(TiO2) nanomaterials, uncoated and coated zinc oxide (ZnO), silicon
dioxide (SiO2) and cerium (IV) oxide (CeO2) NMs,monodispersed silver
(Ag), and multi-walled carbon nanotubes (MWCNTs) of different
lengths and diameters. This broad spectrum of NMs was selected with
the aim of gaining an overview on the applicability of the PCLuS test
method in determining the different types of effects elicited by different
chemical types of NMs.
So far only a limited number of possible mechanisms of action have
been discerned for NMs: direct interactions with cellular structures
(such as membrane lysis), the catalyzing formation of reactive oxygen
species (ROS), and inﬂammation (Landsiedel et al., 2010; Nel et al.,2009, 2013a,b; Shvedova et al., 2012). Metal oxide and metal NMs can
exert cytotoxicity by dissolution and shedding of toxic ions, and carbon
nanotubes can elicit pro-ﬁbrogenic responses (Nel et al., 2013a).
The oxidative stress paradigm has been recognized to play a central
role in the evolvement of NM toxic effects. Depending on their physico-
chemical characteristics, NM-induced ROS can affect different intracel-
lular structures and activate different enzymatic pathways, resulting
in different types of cellular damage (Shvedova et al., 2012). In neutro-
phils, NM-induced ROS can activate myeloperoxidase, which has been
reported to play an important role in the biodegradation of carbon
nanotubes (CNTs; Kotchey et al., 2013; Shvedova et al., 2012).
Activation of redox-sensitive signaling pathways by free radicals can
lead to the induction of inﬂammatory mediators (Dufﬁn et al., 2007a;
Meng et al., 2009; Shvedova et al., 2012; Xia et al., 2008), whereas the
selective activation of mitochondrial cardiolipin can lead to cellular
apoptosis (Hussain et al., 2010; Shvedova et al., 2012). If primary
cellular effects progress, local or systemic organ toxicity and
genotoxicity can occur (Landsiedel et al., 2010). In the lung, apoptosis
is involved in the pathogenesis of a variety of disorders, such as asthma,
emphysema, and acute respiratory distress syndrome (Ahamed et al.,
2011; Hussain et al., 2010). Non-ROS-dependent interference with the
mitotic spindle apparatus might also lead to aneuploidy and ultimately,
potentially, to cancer (Shvedova et al., 2012).
Based upon these considerations, the following endpoints were
selected to investigate whether the spectrum of cellular effects that
have been recorded for the different types of NMs can be reﬂected in
the PCLuS test system: Severe tissue destruction (measured by loss of
PCLuS total protein mass), cytotoxicity (WST-1-measured reduction in
mitochondrial activity), apoptosis (caspase-3/-7 activation), oxidative
stress (reduction or increase of intracellular GSH content), and inﬂam-
mation, i.e. induction of interleukin-1α (IL-1α), tumor necrosis factor-
α (TNF-α), cytokine-induced neutrophil chemoattractant-1 (CINC1;
the structural and functional rat homologue to interleukin-8 (IL-8);
Himi et al., 1997), monocyte chemoattractant protein-1 (MCP-1),
macrophage-colony stimulating factor (M-CSF), and osteopontin
(OPN).
These endpoints comply with the scientiﬁc advice (Hankin et al.,
2011) on fulﬁlling information requirements for nanomaterials under
the EU REACH regulation (Registration, Evaluation, Authorisation of
Chemicals; Anon, 2006). Hankin and co-authors list cellular uptake,
cell viability, oxidative stress, and inﬂammation amongst the relevant
speciﬁc toxicological properties to be addressed as additional endpoints
for NM risk assessment. Finally, histopathological evaluations of the
PCLuS were performed to compare NM effects on in vitro cellular mor-
phology to known histopathological effects upon in vivo NM exposure.
Since PCLuS maintain the pulmonary tissue structure, histopathological
evaluations provide an added value of this test system over cell culture
test systems which only allow recording histological effects on the cel-
lular, but not organ tissue level. Thus PCLuS histopathology might
have the potential to link effects observed ex vivo to the in vivo
situation.
Depending upon their size, inhaled nanomaterials (and their
aggregates and agglomerates) can be deposited in the nasopharyn-
geal, tracheobronchial or alveolar regions of the respiratory tract.
Approximately half of the dose of 20 nm nanomaterials will be
deposited in the alveolar region (ICRP, 1994; Oberdörster et al.,
1994). However, NMs can change their physico-chemical properties
once dispersed in test substance vehicles (e.g. cell culture media)
or upon reaching target cells (Landsiedel et al., 2010). They can
undergo signiﬁcant agglomeration or form a characteristic ‘corona’
by interacting with proteins and phospholipids present in the
biological ﬂuids (Feltis et al., 2012; Monopoli et al., 2011, 2012;
Murdock et al., 2008; Schaefer et al., 2012). Since all of these
changes can alter NM reactivity in biological systems, a deﬁned
dispersion protocol is an important part of any testing method for
nanomaterials to ensure interpretability of test results. In the
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of the stock solution and addition of bovine serum albumin (BSA) to
the cell culture medium to stabilize the dispersion.
Material and methods
Test substances and primary particle characterization
The 16 nanomaterials comprised six different titanium dioxide
(TiO2) nanomaterials (three anatase; NM-100, NM-101, NM-102; two
rutile: NM-103, NM-104; and one rutile-anatase: NM-105), uncoated
(NM-110) and coated (NM-111) zinc oxide, silicon dioxide (SiO2)
nanomaterials produced by precipitation (NM-200) and by thermal
process (NM-203), uncoated cerium (IV) oxide (CeO2) produced
by precipitation (NM-211, NM-212), monodispersed silver (Ag)
produced by precipitation (NM-300K), and 3 multi-walled carbon
nanotubes (MWCNT) of different lengths and diameters (NM-400,
NM-401, NM-402).
Information on the 16 NMs is provided in Table 1 listing the
substance names, their OECD reference number, form of production,
and form of delivery (powder or suspension). Table 1 further presents
the nanomaterials' physico-chemical characteristics as provided by the
JRC (Ispra, Italy), the supplier of all NMs.
All NMs were delivered as dry matter, except for Ag NM-300K,
which was provided in dispersion. The Ag NM-300K dispersant is
an aqueous solution containing the capping agents polyoxyethylene
glycerol trioleate and polyoxy ethylene (20) sorbitan mono-laurat
(Tween 20). This dispersant, on its own, was included as a further,
17th (non-nanoform) test substance (NM-300K DIS) to verify whether
adverse effects induced by the Ag NM-300K dispersion were indeed
caused by the nanoform silver, and not by its dispersant.
Preparation of test substance stock dispersions
Stock dispersions of the test substances were prepared taking into
account personal recommendations from Z. Magdolenova (Health
Effects Laboratory, Kjeller, Norway). As a rule, 3 mg of the test
substances was added to 1 mL of the cell culture medium (serum-free
Dulbecco's modiﬁed Eagle's medium with nutrition mixture F-12 HAM
(DMEM/F-12; Invitrogen, Germany, Product No. 11039-047) containing
1% (v/v) Penicillin/Streptomycin (10 000 IU/10 000 μg/mL; Biochrom
AG, Germany). Based upon the results of pre-tests determining
the size distribution of the nanoparticles in solution, stock solution
concentrations of 4, and 10, 15 mg/mL were selected for TiO2 NM-103,
ZnO NM-111, and TiO2 NM-102, respectively, to ensure a sufﬁcient
amount of the test substance being dispersed in the ﬁnal preparations.
In the case of Ag NM-300K, the stock dispersion concentration of
1 mg/mLwas chosen to take into account that this material was already
fully dispersed in the solution provided by the supplier.
To homogenize the stock dispersion, it was shaken manually and
then sonicated, cooled on ice: First, the samples were sonicated twice
for 2.5 min with a probe sonicator at 200 Watt (Sonoplus Ultraschall-
Homogenisator, Bandelin Electronic, Germany; power: 20-30%; cycle:
100%). Next the dispersion was vortexed for 10 s to disperse particles
that might have attached to the inner wall of the ﬂask (vortex: VWR
international, USA). Afterwards, one part of a 5% BSA solution (w/v;
i.e. 0.1 mL; Sigma-Aldrich, Germany) was added to nine parts stock
dispersion, and one sonication stepwas repeated. Subsequently, thedis-
persionwas stirred on amagnetic stirrer (KA Labortechnik, Germany) at
700 rpm at room temperature for 24 h.
Characterization of the nanoparticles as prepared test items
Characterization of the NMs as prepared test items was performed
using analytical ultracentrifugation (AUC) as described by Wohlleben
(2012). Test substance stock dispersions were prepared 24 h beforeapplication onto the PCLuS and were analyzed on the day of exposure
using the Beckman Ultracentrifuge XLI™ with integrated interference
optics (Beckman Coulter, Palo Alto, CA, USA). Based upon the AUC
measurements, the amount and diameters of each fraction were calcu-
lated independently as described by Wohlleben (2012). Particle sedi-
mentation fractions with particle diameters below 10 μm were
recorded as ‘dispersed concentration’. The results of this characterization
are presented in Table 2a revealing that, apart from Ag NM-300K, SiO2
NM-203, and the MWCNTs, all NMs underwent some degree of agglom-
eration, and all NMs adsorbed BSA.
Preparation of test substance solutions
The ﬁnal dispersions were prepared out of the stock dispersions by
adding cell culture medium. Based upon the respective dispersed con-
centrations of each of the NMs determined by AUC, the dilution factors
were adapted to achieve ﬁnal dispersed test substance concentrations
of 10, 50, 100, 500, and 1000 μg/mL for all 16 NMs, corresponding to
0.3–300 μg/cm2 surface area of the cell culture wells.
For dispersed Ag NM-300K, the dilution factors took into account that
this nanomaterial was delivered in a 10.16% (w/w) dispersed form.
For TiO2 NM-100, the highest concentration was set at 840 μg/mL, the
calculated dispersed concentration. For all other NMs, the dispersed
concentration exceeded 1000 μg/mL so that this concentration could be
set as highest test concentration. Test substance dispersions were pre-
pared in glass vials with at least 5 mL cell culture medium in each vial.
Before usage, the dispersions were stirred for at least 1 h at 700 rpm at
room temperature.
Calculation of effective dose
AUC measurements were also used to determine the effective NM
dose reaching the cells of the PCLuS taking into account the speciﬁc
diffusion and gravitational settling properties of NMs (Hinderliter
et al., 2010; see Supplementary Information (SI) for details on the
calculation of the effective dose).
For agglomerated NMs, sedimentation is expected to be the
predominant parameter determining the effective test substance
dose reaching the PCLuS, and sedimentation was monitored directly
by AUC. For well-dispersed NMs, however, diffusion properties have
been recognized to determine the amount of particles reaching the
tissue cultures and thus have to be included in effective dose calcula-
tions (Teeguarden et al., 2007). Such properties are not reﬂected by
AUC. Therefore, for those NMs for which effective dosages of less
than 50% of the test substance concentration was calculated via
AUC (i.e. for which sedimentation obviously was not the predomi-
nant parameter), the effective dose was additionally calculated
using the ‘In Vitro Sedimentation, Diffusion, and Dosimetry’ (ISDD)
model (Hinderliter et al., 2010), which takes into account both NM
sedimentation and diffusion properties (see also SI for further details
on the ISDD model).
Preparation of precision cut lung slices (PCLuS)
The PCLuS were prepared from nulliparous and non-pregnant
female Wistar Crl:WI (Han) rats (8 to 10 weeks old and free from
clinical signs, obtained from Charles River Laboratories, Germany). All
animal work was performed in an animal facility that holds a certiﬁcate
from the International Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). The animal work was performed in
accordance with the local regulatory agencies, and all study protocols
were in compliance with the federal guidelines.
Animals were euthanized with an intraperitoneal overdose of
pentobarbital sodium (concentration: 160 mg/mL, dose: 300 mg/kg
body weight). The lung lobes and tissues and the lung slices were
prepared as described previously (Wohlleben et al., 2011) using a
Table 1
Test substances and primary particle characterization provided by the supplier (European Commission's Joint Research Centre, Ispra, Italy).
OECD
reference
number
Test
material
Mineral form, form of production,
surface chemistry, physical state,
catalytic activity and conductivity
Purity (%),
impurities
Primary crystal size
(Scherrer, nm),
particle shape
Primary and mean
particle sizes, speciﬁc
surface area
NM-100 Titanium
dioxide
pigment
Anatase, uncoated, comparably large
particle size within TiO2-NM-series
N98.5 XRD pending PPS, TEM: 42–90 nm;
MPS, TEM: 299 nm,
267 nm; SSA: 10 m2/g
NM-101 Titanium
dioxide
Anatase, uncoated,
high photocatalytical activity
91.7 8, XRD: 6 SSA: 320 m2/g
NM-102 Titanium
dioxide
Anatase, uncoated, high
photocatalytical activity
96.0 22, XRD: 20 SSA: 90 m2/g
NM-103 Titanium
dioxide
Rutile, ultraﬁne, hydrophobic 89.0; Al2O3: 6.2% 20, XRD: 20 SSA: 60 m2/g
NM-104 Titanium
dioxide
Rutile, ultraﬁne, hydrophilic 89.8; Al2O3: 6.2% 20, XRD: 20 SSA: 60 m2/g
NM-105 Titanium
dioxide
Rutile-anatase, uncoated N99 21, XRD: 22 SSA: 61 m2/g
NM-110 Zinc oxide Uncoated, white powder N99 70–200 (Horiba light scattering),
spherical
PPS, XRD: 41.5 nm, SSA: 13 m2/g
NM-111 Zinc oxide Coated with 1–4%
triethoxycaprylyl silane,
white powder
N99; coated
modiﬁcation: 96–99
XRD: 33.8, spherical particle size b 200 nm;
mean 130 nm, range 90–190
(Horiba light), SSA: 16 m2/g
NM-200 Synthetic
amorphous
silica PR-A-02
Silicon dioxide produced by
precipitation, white powder
96.5 TEM: 20, spherical primary particles in
the 10–25 nm range, particles
aggregated, SSA: 230 m2/g
NM-203 Synthetic
amorphous
silica PY-A-04
Silicon dioxide produced by
thermal process, white powder
– TEM: 20, spherical, irregular primary particles in
the 5–30 nm range, particles
aggregated, SSA: 226 m2/g
NM-211 Cerium (IV)
oxide
Cerium dioxide, uncoated,
produced by precipitation,
yellowish powder
N95 10.3, cubic XPS: Ce:O ratio 1:2, SSA: 66 m2/g
NM-212 Cerium (IV)
oxide
Uncoated, produced by
precipitation, yellowish powder
N99.5 33, cubic XPS: Ce:O ratio 1:2, SSA 28 m2/g
NM-300K Silver b 20 nm Produced by chemical precipitation
of silver nitrate, monodispersed
with capping agent (monolayer)
stabilizing agents: 4% each of
polyoxyethylene glycerol trioleate
and polyoxy ethylene (20) sorbitan
mono-laurat (Tween 20), silver
content: 10.16% w/w, very viscous,
concentrate orange-brown, yellow
in dilution
10 colloidal, spherical particle size, TEM: 15 nm,
UVvis spectra: D90 b 20 nm
(90% b 20 nm)
NM-300K DIS Ag-dispersant
(control material
for NM-300K)
Aqueous solution containing the
capping agents: 4% each of
polyoxyethylene glycerol trioleate
and polyoxy ethylene (20) sorbitan
mono-laurat (Tween 20), very viscous
– – –
NM-400 Multi-walled
carbon
nanotubes
Specialty graphite, produced by
CCVD, at 20 °C and 1013 hPa: solid
powder, black odorless, insoluble in
water or organic solvent, surface
charge: NA, conductive
N90; impurities:
b10% metal oxide
Ø 9.5, 1.5 μm length, short,
thin, tangled, concentric
tubes, presence of amorphous
carbon on surface of tubes
SSA: 280 m2/g
NM-401 Multi-walled
carbon
nanotubes
Specialty graphite, produced by
CCVD, at 20 °C and 1013 hPa: solid
powder, black odorless, insoluble
in water or organic solvent, surface
charge: NA, conductive
N95, impurities:
metal oxide b 5%
Ø 10–30, 5–15 μm length,
short, thin, tangled, concentric
tubes, presence of amorphous
carbon on surface of tubes
SSA: 300 m2/g
NM-402 Multi-walled
carbon
nanotubes,
Specialty graphite, produced by
CCVD, at 20 °C and 1013 hPa: solid
powder, black odorless, insoluble in
water or organic solvent, surface
charge: NA, conductive
N90, metal oxide b 10% Ø 5–15, 0.1–10 μm length,
short, thin, tangled concentric
tubes, presence of amorphous
carbon on surface of tubes
SSA: 250–300 m2/g
• PPS: primary particle size; MPS: mean particle size; determined by transmission electron microscopy (TEM) or x-ray photoelectron spectroscopy (XPS).
• Primary crystal size; determined with x-ray diffraction (XRD), TEM, or dynamic light scattering (DLS)
• SSA: speciﬁc surface area; determined by the method of Brunauer–Emmett–Teller)
• CCVD: catalytic chemical vapor deposition
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to obtain precision-cut lung slices with a diameter of 8 mm and a
thickness of approximately 200–250 μm.
To ensure reproducible quality of the PCLuS, only rats of the age of 8
to 10 weekswere used, which is the same age of rats in in vivo inhalation
studies. Thereby all organs used for PCLuS cutting were of comparablesize, so that constant amounts of PCLuS (90–120 slices per animal)
were obtained. During lung preparation, care was taken that the temper-
ature of the agarose-medium solution used to ﬁll the lungs prior to slice
cutting did not exceed body temperature and that the amount of solution
applied did not increase organ pressure, thereby avoiding physical de-
struction of the lung tissues. For the core cut, the crucial step in the
Table 2a
Characterization of the particles dispersed in bovine serum albumin (BSA)-containing cell culture medium determined by AUC: Mean particle diameter, weight percentage of dispersed
particles (b10 μm), and concentration of non-adsorbed BSA.
OECD reference number Test material NM diameter with BSA (nm) Dispersed NM (weight%) Non-adsorbed BSA (mg/mL)
NM-100 TiO2 262 28 2.4
NM-101 TiO2 428 39 2.5
NM-102 TiO2 495 22 3.2
NM-103 TiO2 118 22 2.6
NM-104 TiO2 105 48 3.1
NM-105 TiO2 79 66 2.8
NM-110 ZnO 176 75 2.2
NM-111 ZnO 310 33 2.6
NM-200 SiO2 65 47 2.8
NM-203 SiO2 58 125 2.9
NM-211 CeO2 146 and N309a 43 3.0
NM-212 CeO2 107 84 3.2
NM-300K Ag 11 100 3.6
NM-400 MWCNT 30 90 2.7
NM-401 MWCNT 219 94 3.5
NM-402 MWCNT 36 96 2.8
• AUC: analytical ultracentrifugation
a Bimodal mean particle size distribution
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age. Transfer of the prepared PCLuS to the vials or cell culture wells was
performed with a round device only, taking care not to squeeze the
tissues.
PCLuS exposure to test substances, negative and positive controls
For exposure of the PCLuS to the test substance, two lung slices per
well were transferred to a 24-well plate and incubated in 500 μL cell
culture medium for 24 h under cell culture conditions (37 °C, 5% CO2,
95% humidity). Applying two slices of a thickness of approximately
250 μm each per well (and not e.g. one slice twice the thickness)
ensured that sufﬁcient tissue material was exposed to the test
substances and that all cells of the slices could come into contact with
the cell culture medium and the test substances.
Additional two slices per well were used for incubations of the
negative and positive controls. DMEM/F-12 medium was used as
negative control (NC). The following positive controls (PC) were used,
dissolved in 500 μL solution, to verify test system inducibility:
• 0.1% Triton X-100 (SigmaAldrich, Germany) for the cytotoxicity assay
and for histopathology;
• 0.5 μM staurosporine (Sigma Aldrich, Germany) for the caspase-3/-7
assay;
• 10 mM DL-buthionine-[S,R]-sulfoximine (BSO) (Sigma Aldrich,
Germany) for the GSH assay.
For the cytokine release assays, the suitability of 100 ng/mL lipo-
polysaccharide (LPS) (Sigma Aldrich, Germany) as PC was investigated.
LPS is commonly used as PC in cytokine assays (Feltis et al., 2012;
Henjakovic et al., 2008; Switalla et al., 2010a). However, LPS has a differ-
ent mode of immunological action than NMs: Being bacterial products,
LPS bind to toll-like receptors 2 and 4 that modulate pathogen-
induced immune reactions (Janardhan et al., 2006; Lorne et al., 2010;
Saito et al., 2005). NMs, on the other hand, are engineered particles
causing generalized neutrophilic or eosinophilic inﬂammatory
responses (Cho et al., 2010; Feltis et al., 2012). Speciﬁcally, in rats LPS
has been observed to induce IL-1α, TNF-α, CINC1 (IL-8), and in some
cases, M-CSF, but not OPN or MCP-1 (unpublished in-house data).
Thus LPS does not induce all of the tested cytokines. Furthermore LPS
measurements frequently had high coefﬁcients of variation and repeat-
edly did not meet the respective PC-related acceptance criteria (see
below). Therefore it was decided not to use LPS as PC in the cytokine
assays, and calculation of the x-fold increase of test substance results
in relation to the NCwas applied instead to verify test system inducibil-
ity in the cytokine assays.Assay performance
After incubating the PCLuS with the respective test substance and
control solutions for 24 h,
• Reduction in mitochondrial activity (WST-1 assay) was measured
directly in the PCLuS, just as histopathology was performed using
intact PCLuS.
• Intact PCLuSwere also submitted to the caspase-3/-7 activation assay,
where PCLuS lysation however was the ﬁrst step of the commercial
test kit (see below).
• Total protein content, glutathione content, and intracellular
interleukin-1α (IL-1α) were determined in lysates of exposed
PCLuS, and
• PCLuS supernatants were used to determine the levels of the extracel-
lular cytokines (see below).
For preparation of the PCLuS lysates for GSH and IL-1α measure-
ments, the two PCLuS of each well were freeze–thawed three times in
1 mL phosphate-buffered saline (PBS buffer; Biochrome AG, Germany)
containing 2 mM EDTA (Biochrome AG, Germany) and 0.2% protease
inhibitor cocktail (Sigma Aldrich, Germany). During this procedure,
tissues were shock-frozen in liquid nitrogen and then thawed in a
water bath at 37 °C three times each. Thereby the cell–cell interactions
are destroyed. After centrifugation (20 min at 6000 g; centrifuge Rotina
35R/Hettich AG, Switzerland), intracellular glutathione and IL-1α are
present in the PBS buffer. This supernatant was collected and stored at
−80 °C until glutathione and IL-1αwere determined.
All tests were performed in duplicate (biological replicates), and all
measurementswere performed twice (technical replicates). Test results
are expressed asmeans of the technical and biological replicates further
indicating the distance of the lower and upper technical means to the
overall mean value.
Determination of protein content of PCLuS. The colorimetric BCA
(bicinchoninic acid) protein assay (Pierce® BCA Protein Assay Kit; Ther-
mo Fisher Scientiﬁc, Inc., USA) was performed to determine the protein
content of the PCLuS. This assay combines the reduction of Cu2+ to
Cu1+ by protein in an alkaline medium with the colorimetric detection
of Cu1+ cations by BCA (http://www.piercenet.com/browse.cfm?
ﬂdID=02020101).
To prepare PCLuS lysates for the protein content measurements, the
two lung slices present in each well were transferred to lysis buffer
(500 μL of 0.1% Triton X-100 in PBS) containing 0.2% (v/v) protease
inhibitor cocktail (Sigma Aldrich, Germany) and incubated under cell
culture conditions for 1 h. Cell lysates were centrifuged for 3 min at
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of protein content.
For determination of the total protein content, 200 μL BCA working
reagent were added to 25 μL of the PLuCS lysates in a clear 96-well
plate and mixed carefully. The plate was incubated under cell culture
conditions for 30 min. Total protein content was measured as net
absorbance at 570 nm in a multilabel counter (Wallac Victor 3 1420,
Perkin Elmer, USA) using BSA as a standard. For each test run, sigmoidal
BSA standard curves were prepared and calculated using the GraphPad
Prism6® software in a free trial version for Mac (www.graphpad.com).
The determination of PCLuS protein mass served several purposes:
• First, it was used as a quality control to verify acceptable thickness of
the lung slices, as reﬂected by total protein contents between 150 and
450 μg/mL (based upon unpublished historical data from BASF). All
PCLuS (used in non-cytotoxic measurements) met this premise.
• Second, it was used to recognize NMs causing severe tissue destruction,
as reﬂected by reductions in total protein content below 150 μg/mL, i.e.
below the lowest NC measurement.
• Third, it was used to relate the cytotoxicity test results to tissuemass of
the PCLuS. (Since the lung slices had to be lysated for conducting the
BCA protein assay, only cytotoxicity test results could be related to
PCLuS total protein since only theWST-1 assay does not require lysating
the tissue slices).
Of note, the determined total protein content most likely to also
includes a proportion of the bovine serum albumin that had been
added to the NM dispersions, as was evident, e.g. from the histopatho-
logical evaluations where nanoparticles were present in the tissue
slices. However, this proportion of BSA was considered to be negligible
since only one part of the 5% BSA solution had been added to nine parts
of the stock solution during preparation of the NM stock solutions, and
no further BSA had been added during preparation of the ﬁnal test
substance concentrations.
Determination of cytotoxicity (i.e. changes in mitochondrial activity). Cy-
totoxic effects of the NMs were assessed by measuring changes in
mitochondrial activity (determined via reduction of water-soluble
tetrazolium WST-1 to formazan using the Cell Proliferation Reagent
WST-1; Roche, Germany). PCLuS were incubated for 2 h under cell
culture conditions with 500 μLWST-1 reagent (1:10 ﬁnal dilution in cul-
ture medium) per well. Prior to testing, the test substance supernatants
were centrifuged for 5 minat 300 g to collect thenanoparticles at the bot-
tom of the wells. Afterwards 100 μL supernatant were transferred to a
clear 96-well plate and measured in a multilabel counter (Wallac Victor
3 1420, Perkin Elmer, USA). Formazan absorbance (optical density, OD)
was measured at 450 nm with a reference wavelength of 690 nm. The
absorbance values were expressed in relation to the total protein (TP)
content of the respective lung slices (OD/TP).
Determination of caspase-3/-7 activation. Caspase-3 and -7, two cyste-
ine aspartic acid-speciﬁc proteases, have been recognized to coordinate
the execution phase of apoptosis by cleaving multiple structural and re-
pair proteins thereby playing key effector roles in apoptosis (Hussain
et al., 2010; Slee et al., 2001). Therefore, apoptotic reactions of the NMs
were evaluated by determining activation of caspase-3 and -7, using
the Caspase-Glo® 3/7 Assay (Promega Corporation, USA), which was
performed directly using the two PCLuS of each well.
The tissue slices intended for measurement of caspase-3 and -7
activities were transferred to 300 μL Caspase-Glo® 3/7 Reagent per
well of a 24-well plate. This reagent induces cell lysis, followed by
caspase cleavage of the substrate, and generation of the luminescent
signal. Upon addition of the reagent, the slices were incubated for
60 min at room temperature in the dark. Afterwards 100 μL superna-
tants were transferred to a luminescence-capable, black 96-well plate.
(Due to the ﬁbrous shape of the MWCNT, the respective supernatants
were centrifuged at 100 000 g for 30 min before testing to preventtest substance interference with the luminescence reaction.) Lumines-
cence (expressed in Relative Luminescence Units; RLU) was read in a
multilabel counter (Wallac Victor 3 1420, Perkin Elmer, USA). PCLuS
treated with staurosporine were used as positive control. Positive
control measurements were set as 100% caspase-3/-7 induction, and
test results were expressed relative to the positive control.
Determination of oxidative stress. Glutathione (GSH) is an important
intracellular antioxidant defending cells against harmful compounds
(Monteiller et al., 2007; Pastore et al., 2003). Therefore oxidative stress
was determined by measuring changes in cellular glutathione using
the GSH-Glo™ Glutathione Assay (Promega Corporation, USA). This
luminescence-based assay is performed in two steps, i.e. the GSH
reaction and the luciferin detection. For the ﬁrst step, 50 μL of tissue
extract and 50 μL GSH-Glo™ Reagent 2×were added to a luminescence
capable, black 96-well plate and incubated for 30 min at room temper-
ature in the dark. Thereafter 100 μL reconstituted Luciferin Detection
Reagent were added to each well, mixed brieﬂy on a plate shaker (ZLE
164, Amersham, United Kingdom), and incubated again under the
same conditions. (Due to the ﬁbrous shape of the MWCNT, the respec-
tive supernatants were centrifuged at 100 000 g for 30 min before
testing to prevent test substance interference with the luminescence
reaction.) After 15 min, the resulting luminescence (expressed in RLU)
was read in a multilabel counter (Wallac Victor 3 1420, Perkin Elmer,
USA). PCLuS treated with BSO were used as positive control. The
luminescence measured in the negative control (untreated PCLuS)
was set as 100% amount of GSH, and test results were expressed relative
to the negative control.
Determination of cytokine induction. Pre-tests were performed with
TiO2 NM-105, ZnO NM-110, and MWCNT NM-400 to determine which
cytokines were best induced in PCLuS. For this purpose, samples of
PCLuS supernatants and extracts frozen at−80 °C were sent to Myriad
RBM (Myriad Rules-Based Medicine, Austin, TX, USA). Using xMAP
technology (Luminex Corporation, Austin, TX, USA), 56 different
cytokines from either the supernatant or PCLuS extract were measured.
Based upon the results of these pre-tests and taking into account
cytokine measurements in bronchoalveolar lavage and lung tissue
homogenate from in vivo inhalation studies, induction and secretion
of the following inﬂammatory mediators were determined:
Measured intracellularly, IL-1α, and measured extracellularly in the
PCLuS supernatant, TNF-α, CINC-1 (IL-8), MCP-1, M-CSF, and OPN.
These cytokines reﬂect three different stages and aspects of inﬂamma-
tion as recommended byMa-Hock et al. (2009a):Mediatorsmodulating
immune reactions (IL-1α and TNF-α); mediators inducing inﬁltration
of inﬂammatory cells into the lung tissue (CXC-chemokines, e.g. CINC1
(IL-8); and CC-chemokines, e.g. MCP-1); mediators inducing prolifera-
tion of hematopoietic cells (M-CSF) or sessile cells present in the lung
(OPN).
The external pre-test cytokine measurements were repeated in-
house for MWCNT NM-400. For technical reasons, they could not be
repeated for TiO2 NM-105. For completeness, the RBM-gained cytokine
induction data for this NM are presented in the respective tables
(Supplementary Information (SI) Tables S6-S10), however were
excluded from the evaluation due to methodological differences.
The following commercial assays were used:
• DuoSet rat IL-1α/IL-1 F1; cat. no. DY500; R&D Systems, Inc., USA;
• Flow Cytomix Simplex Kit TNF-α, cat. no. BMS 8622 FF, eBioscience,
Vienna, Austria;
• Quantikine rat CINC1, cat. no. RCN100, R&D Systems, Inc., USA;
• Flow Cytomix Simplex Kit MCP-1 rat, cat. no. BMS 8631 FF,
eBioscience, Vienna Austria;
• Quantikine Mouse M-CSF, cat no. MMC00, R&D Systems Inc., USA;
• Quantikine mouse osteopontin, cat. no. MOST00; R&D Systems, Inc.,
USA.
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concentrations, i.e. 10, 100, and 1000 μg/mL. For MWCNT NM-400, the
highest test substance concentration was 500 μg/mL. The Flow Cytomix
assays (Fluorescence Bead Immunoassay; FBIA) were applied on a
FACSCalibur™ ﬂow cytometer (Becton Dickinson, Germany) using the
FlowCytomix Pro Software (version 2.3, Bender MedSystems, Austria)
for evaluations. The DuoSet and Quantikine ELISAs were performed
with a Sunrise™MTP Reader (Tecan AG, Switzerland) using the Magel-
lan Software provided by the instrument producer. All assays were val-
idated with the PCLuS extract or culture supernatant (see assay criteria
in the Supplementary Information, Table S1). Test results were
expressed as x-fold increase of cytokine levels relative to the negative
control.
Histopathology. For histopathological investigations, the PCLuS were
ﬁxed immediately after exposure for a minimum of 24 h in approxi-
mately 1 mL 4% formaldehyde solution (BASF SE, Germany) followed
by the preparation of Hematoxylin and Eosin (Sigma, Germany) stained
cross sections. Triton X-100-treated PCLuS were used as positive con-
trols for histopathological evaluation. Histopathological evaluations
were not performed for PCLuS tested on TiO2 NM-105, ZnO NM-110,
or MWCNT NM-400.
Statistical analysis
Test substance availability and stability only allowed one run of tests
for each of the nanomaterials. To assess the reliability of test results and
test runs, speciﬁc test result-, NC- and PC-related acceptance criteria
(AC) were laid down for all assays (Lauenstein et al., 2012). As regards
test result-related AC, for the protein and WST-1 assays, the maximum
difference between 2 technical replicates was set to be≤0.3 OD; and for
the GSH and caspase-3/-7 assays, themaximumdifference between du-
plicate RLU measurements relative to the mean value of duplicate RLU
measurements was set to be ≤30%. All test results of all assays fulﬁlled
these test result-related AC.
The NC-related AC served to determine the intactness and viability
of the tissue slices and the PC-related AC to determine PCLuS inducibil-
ity by a known reacting substance. The threshold values for these AC
were set based upon the respective values laid down by Lauenstein
and co-authors taking into account the overall results of the study at
hand. An overview of the respective NC- and PC-related AC laid down
for each assay is provided in Table 9).
Test results were excluded from further evaluation if the NC-related
or PC-related AC were not met. By derogation of this provision, test re-
sults were included on a case-by-case basis, if statistical signiﬁcance of
the test results indicated that test results were sufﬁciently different
from high negative control values (in the case of failure of the NC to
meet NC-related AC) or that the test system had been inducible in
spite of the failure of the PC tomeet the PC-related AC. To determine sta-
tistical signiﬁcance of test results (p ≤ 0.05), linear dose-responses
were evaluated by testing for linear trend (95% signiﬁcance level)
using the EXCEL function RGP.
Additionally, NC conﬁdence intervals, i.e. 95% prediction limits of the
NC, were calculated with EXCEL from the means of all NC of a given
assay and their standard deviation (STD) according to the formula
[mean+/− (root(1 + 1/N)*t(N-1) *STD],with [t(n-1)] being the fractil
of the t distribution with n-1 degrees of freedom. Thereby threshold
values were determined above which measurements were considered
to be biologically relevant, i.e. exceeding the range of values recorded
for the NC. If no statistically relevant test results were recorded in test
runs in which the NC exceeded the 95% conﬁdence limit of the mean
of all NC, it could not be determined whether this lack of effect was an
artifact due to high NC reactivity or if it was indeed an indication of a
lack of biological effect.
To determine intra-laboratory assay reproducibilities, coefﬁcients of
variation (CV%) exceeding 20% or 50%, respectively, were recorded.These CV% threshold values were set in accordance to intra-assay and
inter-assay precision values provided by test kit suppliers or reported
in the literature (see Table 9) adjusted to complywith assay variabilities
observed in previous PCLuS studies (Lauenstein et al., 2012; Wohlleben
et al., 2011).
Results
Calculation of effective dose
The results of the AUC and ISDD calculations of the effective NMdos-
ages reaching the PCLuS after 12- and 24-hour test substance exposure
are presented in Table 2b. Making use of the AUCmeasurements of sed-
imentation, vast differences in the relative effective dosages ranging
from 100% and 99% (for TiO2 NM-100 and ZnO NM-110, respectively,
corresponding to 300 and 297 μg/cm2 for the highest test substance
concentration of 1000 μg/mL) down to 2% for MWCNT NM-400 and
NM-402, each, were recorded (corresponding to 6 μg/mL for the
1000 μg/mL test substance concentration). Also within the group of
TiO2 NMs, differences in the relative effective dosages between 100%
(NM-100) and 44% (NM-105) were calculated by AUC sedimentation
estimations. The differences in relative effective dosages observed for
the SiO2 NMs (81% for NM-200 versus 24% for NM-203), are likely to
be explained by differing agglomeration stabilities of these two mate-
rials, since both SiO2 NMs have similar primary and secondary charac-
teristics (Tables 1 and 2a).
Based upon the ISDD calculations, effective dosages of the 1000 μg/mL
(300 μg/cm2) test substance concentration were calculated ranging from
80 μg/cm2 for ZnO NM-111 down to 17 μg/cm2 for MWCNT NM-401
(after 24 h test exposure). As compared to the AUC calculations, the
ISDD effective dosage values were lower for the moderately dispersed
TiO2 NM-105, ZnO NM-111, and SiO2 NM-200, but higher for the ‘fully’
dispersed particles (below 10% effective dose in AUC), i.e. SiO2 NM-203,
Ag NM-300K, and all MWCNT.
Considering that diffusion propertieswere not taken into account for
the AUC-based calculations and that the critical parameter of number of
particles in the individual agglomerates was chosen rather arbitrarily
for the ISDD calculations, both approaches only provide estimations of
the effective dosages. The respective values obtained with either meth-
od, nevertheless are in comparable ranges (Table 2b).
In vitro–in vivo comparisons are based upon the assumption that the
effective dose reaching 1 cm2 of tissue culture in vitro corresponds to
the effective dosage reaching 1 cm2 of lung surface in vivo. Comparing
the AUC and ISDD calculations (for the strongly agglomerated and
well dispersed NMs, respectively) to highest in vivo dosages (as deter-
mined in previous rat short-term inhalation studies) reveals that the ef-
fective in vitro dosages of the highest test substance concentration of
1000 μg/mL were consistently higher than the respective in vivo dos-
ages, i.e. by orders of magnitude of at least 100 (Table 2b). Hence, the
lowest test substance concentration of 10 μg/mL is more likely to reﬂect
dosages applied in vivo.
Since, however, the focus of the present study aimed at determining
the applicability of the PCLuS test system in detecting the spectrum of
early cellular effects that may be caused by NMs, the dose range of
10–1000 μg/mL wasmaintained throughout the study to ensure induc-
ing observable effects in all of the endpoint-speciﬁc assays.
Fulﬁllment of acceptance criteria and test result reproducibility
An overview of the fulﬁllment of the respective assay-speciﬁc NC-
and PC-related AC is presented in Table 9 (with details in SI Tables S2–
S11). Accordingly, all NC and PC fulﬁlled the respective AC in the BCA
protein assay, and in the WST-1 assay, only the NC for CeO2 NM-212
did not meet the NC-related AC. Since however signiﬁcant cytotoxicity
was measured for this substance at 1000 μg/mL, it was included in the
evaluation. The proportion of NC not meeting their respective AC was
Table 2b
Estimation of effective dose of the 1000 μg/mL test substance concentration of 16 OECD reference nanomaterials reaching the PCLuS after 12- and 24-hour test substance exposure as
calculated via analytical ultracentrifugation (AUC) and via ISDD model for well-dispersed NM (deﬁned as b50% effective 24 h-dose determined by AUC-based calculations).
OECD reference
number
Test
material
% Dose after
12 h (AUC)
% Dose after
24 h (AUC)
Corresponding
to μg/cm2 (a)
Dose (μg/cm2)
after 12 h (ISDD)
Dose (μg/cm2)
after 24 h (ISDD)
Highest in vivo
dose in STIS (b)
NM-100 TiO2 97 100 300 – –
NM-101 TiO2 46 62 186 – –
NM-102 TiO2 66 82 246 – –
NM-103 TiO2 32 60 180 – –
NM-104 TiO2 26 48 144 24 35
NM-105 (c) TiO2 24 44 132 25 38 0.4 μg/cm2 (50 mg/m3)
0.56 μg/cm2 (88 mg/m3)
NM-110 ZnO 90 99 297 – –
NM-111 ZnO 84 96 288 80 80 0.17 μg/cm2 (12.5 mg/m3)
NM-200 (c) SiO2 15 27 81 23 32 0.09 μg/cm2 (25 mg/m3)
NM-203 SiO2 4 8 24 23 32
NM-211 CeO2 64 87 261 – – 0.07 μg/cm2 (25 mg/m3)
NM-212 CeO2 43 68 204 – – 0.13 μg/cm2 (25 mg/m3)
NM-300K (c) Ag 2 4 12 53 69
NM-400 (c) MWCNT 1 2 6 33 46 0.01 μg/cm2 (2.5 mg/m3)
NM-401 (c) MWCNT Not determined Not determined 12 17
NM-402 (c) MWCNT 1 2 6 30 42
AUC: calculation of effective dose based upon analytical ultracentrifugation (AUC) measurements;
ISDD: calculation of effective dose making use of the ‘In Vitro Sedimentation, Diffusion, and Dosimetry’ (ISDD) model (Hinderliter et al., 2010)
Not determined: determination not possible for technical reasons
(a) Corresponding tissue culture surface area-based concentrations upon 24 h test substance exposure as calculated for the highest test substance concentration (1000 μg/mL = 300 -
μg/cm2)
(b) STIS: Short-term inhalation study; dosages based uponMa-Hock et al. (2009a) for TiO2 NM-105; Klein et al. (2012) for NM-111 and a substance similar to SiO2 NM-200; unpublished
in-house data for CeO2 NM-211 and NM-212; and Ma-Hock et al. (2009b) for MWCNT NM-400.
(c) ISDD calculations taking into account
- NM density as determinedwith a water pycnometer (densities: NM-105 = 4.2 g/cm3; NM-200 = 2.2 g/cm3; NM-300K = 10.49 g/cm3; NM-400 = 1.8 g/cm3; NM-401 = 1.8 g/cm3;
NM-402 1.8 g/cm3). Of note, NM density did not inﬂuence on effective dose: Calculating effective MWCNT dose with density = 1.02 provided the same results indicating that for these
substances, transport is dominated by diffusion and not by particle deposition.
- NM primary particle size (see Table 1)
- NM hydrodynamic diameter in test substance dispersions (see Table 2a)
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damage is most likely to have occurred during PCLuS preparation or
handling in those NC that failed to meet the respective NC-related ac-
ceptance criteria. Failure to meet the PC-related AC was most
pronounced in the caspase-3/-7 assay.
Test runs, in which the NC exceeded 95% of the conﬁdence limit of
the mean of all NC of the respective assay (and in which no statistically
signiﬁcant test results were recorded), occurred three times each in the
GSH and MCP-1 assays, twice in the TNF-α assay, and once each in
the caspase-3/-7 and CINC1 assays (SI Tables S4, S5, S7, S8, S9). As
discussed above, in these test runs, it is not possible to determine
whether the lack of statistically signiﬁcant effect truly reﬂects a lack of
biological activity.
Test result reproducibility alsowas best in the BCAprotein andWST-
1 assays (Table 9 with details in SI Tables S2–S11). In the protein assay,
7 of 119 (6%) test results had CV% N20%. In the WST-1 assay, 5 of 91
test results had CV% N20% and one additional test result a CV% N50%
(together: 7%). In contrast, in the GSH and caspase-3/-7 assays, 23 and
13 of 81 test results (28% and 16%), respectively, had CV% N20%. In the
cytokine assays, up to half of the test results had CV% N20%.Table 3
OECD reference nanomaterials causing PCLuS tissue destruction.
NM; μg/mL NM-110 ZnO NM-111 ZnO
NC 275.1 ± 19.2 422.0 ± 28.4
10 149.7 ± 8.0 145.0 ± 5.9
50 130.4 ± 12.3 162.1 ± 2.9
100 134.4 ± 11.4 161.3 ± 0.0
500 135.1 ± 3.5 144.0 ± 2.3
1000 126.4 ± 12.8 138.5 ± 23.9 a
PC 63.4 ± 7.4 65.3 ± 3.2
• Total protein content (μg/mL); all data expressed as mean of duplicate testing and distance o
• PCLuS tissue destruction: PCLuS total protein content b150 μg/mL as determined in the Pier
• a: CV% N20%PCLuS tissue destruction
For the following test substances, the PCLuS test system resulted in
protein concentrations below the threshold limit of 150 μg/mL, pointing
to severe PCLuS tissue destruction: for ZnONM-110 at all test substance
concentrations (10–1000 μg/mL), for ZnO NM-111 at 10, 500, and
1000 μg/mL, for Ag NM-300K at 50–1000 μg/mL, and for Ag dispersant
NM-300K DIS at 1000 μg/mL (Table 3 and SI Table S2). The latter results
reveal that the silver nanomaterial is more toxic than its dispersant.
Therefore the dispersing agent did not predominantly cause the effects
observed for Ag NM-300K. Since tissue destruction is an overriding
effect, further investigations were not performed with these four
substances.
Cytotoxicity
For a total of six test substances, the PCLuS test system revealed
signiﬁcant cytotoxicity, as determined by reduced mitochondrial
activity in the WST-1 assay: for TiO2 NM-100 at 500 and 1000 μg/mL,
for TiO2 NM-101 at 100, 500, and 1000 μg/mL, for both CeO2 NM-211NM-300K Ag NM-300K DIS Ag dispersant
241.8 ± 29.2 196.5 ± 15.5
172.7 ± 5.3 190.7 ± 1.0
107.1 ± 8.3 206.0 ± 0.3
83.5 ± 28.6 a 195.1 ± 1.8
67.0 ± 1.3 193.8 ± 19.8
50.1 ± 4.4 60.9 ± 1.9
19.5 ± 4.1 a 19.4 ± 0.3
f upper and lower value to mean
ce® BCA protein assay
Table 5
OECD reference nanomaterials causing signiﬁcant changes in caspase-3/-7 activities in
PCLuS.
NM;
μg/mL
NM-100
TiO2
NM-200
SiO2
NC 34.9 ± 2.5 30.1 ± 5.0a
10 33.1 ± 0.7 37.2 ± 1.6
50 35.7 ± 3.8 36.1 ± 4.4
100 34.8 ± 1.3 33.6 ± 1.8
500 53.0 ± 0.2* 41.7 ± 4.2*
1000 46.8 ± 3.1* 39.7 ± 0.1*
PC 70 600 ± 7303 = 100.0% 87 744 ± 6494 = 100.0%
• NC: negative control (DMEM/F-12); PC: positive control (Staurosporine); RLU: Relative
Luminescence Unit
• Caspase-3/-7 assay:
RLU expressed relative to PC which was set as 100% and distance of upper and lower
value to mean
• a: CV% N 20%
• *Statistical signiﬁcance (p ≤ 0.05) in trend analysis
Table 4
OECD reference nanomaterials causing signiﬁcant cytotoxicity in PCLuS in the WST-1 assay at concentrations not causing tissue destruction (cf. Table 3).
NM; μg/mL NM-100 TiO2 NM-101 TiO2 NM-211 CeO2 NM-212 CeO2 NM-401 MWCNT NM-402 MWCNT
NC 47.4 ± 5.7a 49.8 ± 2.2 66.4 ± 5.3 28.4 ± 1.1c 63.4 ± 0.1 69.1 ± 4.2
10 53.8 ± 2.9 50.2 ± 5.3 66.0 ± 0.1 33.6 ± 1.5 61.1 ± 3.5 58.7 ± 3.5
50 45.7 ± 3.1 45.4 ± 2.3 71.4 ± 3.9 34.0 ± 3.0 74.9 ± 1.8 63.0 ± 2.2
100 43.5 ± 5.8 42.6 ± 2.8* 73.4 ± 2.0 30.9 ± 0.7 66.1 ± 0.5 61.1 ± 0.3
500 38.8 ± 3.9* 41.1 ± 4.2* 60.3 ± 2.4 29.3 ± 0.3 61.8 ± 1.7 40.7 ± 0.0*
1000 41.0 ± 2.0* 38.8 ± 1.3* 61.0 ± 3.6* 27.3 ± 0.7* 49.0 ± 1.7* 43.5 ± 2.0*
PC 37.2 ± 20.8b 16.9 ± 0.8 10.8 ± 0.5 10.3 ± 0.5 13.7 ± 0.5 20.9 ± 1.2a
• NC: negative control (DMEM/F12); PC: positive control (Triton X-100)
• OD: optical density; TP: total protein
• All data expressed as mean OD of duplicate testing related to mean PCLuS protein contents of the respective well (TP) and distance of upper and lower value to mean
• The highest test substance concentration for NM-100 was 840 μg/mL, i.e. its calculated dispersed concentration
• a: CV% N 20%
• b: CV% N 50%
• c: NC did not meet respective acceptance criterion
• *Statistical signiﬁcance (p ≤ 0.05) in trend analysis
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MWCNT NM-402 at 500 and 1000 μg/mL (Table 4 and SI Table S3).
Caspase-3/-7 activation
Signiﬁcant activation of caspase-3 and -7 without corresponding
cytotoxicity in the PCLuS test system was induced by SiO2 NM-200 at
500 and 1000 μg/mL. Signiﬁcant activation of caspase-3 and -7 with
concurrent signiﬁcant cytotoxicity was recorded for TiO2 NM-100 at
test substance concentrations 500 and 840 μg/mL (Table 5 and SI
Table S4).Table 6
OECD reference nanomaterials causing signiﬁcant changes in GSH levels in PCLuS at concentra
NM;
μg/mL
NM-101
TiO2
NM-102
TiO2
NC 14 376 ± 705 = 100.0% 11 649 ± 1216 = 100.0
10 133.5 ± 0.1* 122.5 ± 7.5
50 149.6 ± 17.1* 112.5 ± 2.6
100 Cytotoxicity 122.8 ± 3.8
500 Cytotoxicity 113.5 ± 0.7
1000 Cytotoxicity 136.1 ± 3.8*
PC 24.0 ± 0.2 27.9 d
• NC: negative control (DMEM/F-12); PC: positive control (DL-Buthionine-[S,R]-sulfoximine);
• GSH assay:
RLU expressed relative to NC which was set as 100% and distance of upper and lower value
• a: CV% N 20%
• b: CV% N 50%
• c: NC did not meet respective acceptance criterion; d: only one measurement
• *Statistical signiﬁcance (p ≤ 0.05) in trend analysisRegardless of cytotoxicity, for TiO2 NM-100 and SiO2 NM-200
(signiﬁcant caspase activation), as well as TiO2 NM-101, NM-102, NM-
103, and SiO2 NM-203 (non-signiﬁcant caspase activation), the highest
RLU measurements were obtained at the second highest test substance
concentration (500 μg/mL), and for TiO2 NM-105 andMWCNTNM-400,
at 100 μg/mL (non-signiﬁcant caspase activation) (Table 5 and SI
Table S4).
Oxidative stress
Due to overriding cytotoxicity, only test results obtained at non-
cytotoxic test substance concentrations were evaluated in the GSH
assay. In the PCLuS test system, signiﬁcant changes in intracellular
GSH content at non-cytotoxic test substance concentrationswere elicit-
ed by TiO2 NM-101 at 10 and 50 μg/mL, by TiO2 NM-102 andNM-104 at
1000 μg/mL, and byMWCNTNM-401 at 500 μg/mL. In all cases, increases
in GSH content were measured, presumably reﬂecting a cellular defense
response to ROS. For no test substance signiﬁcant reductions in GSH
content were determined, (Table 6 and SI Table S5).
Cytokine induction
A total of 12 NMs were evaluated in the cytokine induction assays,
i.e. all NMs that were not ruled out due to overriding tissue destruction
additionally excluding the test results obtained for TiO2 NM-105 in the
external laboratory due to methodological differences (see above;
Material and methods; Determination of cytokine induction), and
once more excluding cytotoxic test substance concentrations from the
evaluation.tions causing neither tissue destruction nor cytotoxicity, (cf. Tables 3 and 4).
NM-104 TiO2 NM-401 MWCNT
% 18 676 ± 2623 = 100.0% 6368 ± 284 = 100.0%c
84.0 ± 11.0 82.5 ± 20.5a
72.4 ± 11.3a 85.3 ± 6.8
81.4 ± 0.3 87.0 ± 3.9
85.8 ± 8.0 111.1 ± 0.8*
115.1 ± 15.7* Cytotoxicity
16.7 d 27.9 ± 1.4
RLU: Relative Luminescence Unit
to mean
Table 7
OECD reference nanomaterials causing signiﬁcant changes in cytokine induction (pg/mL) in PCLuS at concentrations causing neither tissue destruction nor cytotoxicity, (cf. Tables 3 and 4).
Note: Joint footnotes for Table 7a–f at bottom of Table 7f.
NM;
µg/mL
NM;
µg/mL
NM;
µg/mL
NM;
[µg/mL]
NM;
[µg/mL]
NM;
[µg/mL]
NM-101
TiO2
NM-104
TiO2
NM-200
SiO2
NC 200 = 1.0 500 = 1.0 400 = 1.0 a
10 1.8 * 1.0 1.1 a
100 cytotoxicity 1.4 * 1.4
1000 cytotoxicity 1.4 * 2.0 *
NM-100
TiO2
NM-200
SiO2
NM-211
CeO2
NM-212
CeO2
NM-402
MWCNT
NC 26.2 = 1.0 a 29.9 = 1.0 22.7 = 1.0 b 33.7 = 1.0 a 18.5 = 1.0 a
10 1.5 1.5 a 2.3 1.4 1.4
100 2.1 * 2.0 * 3.5 * 2.7 * 1.8 c *
1000 cytotoxicity 2.0 * cytotoxicity cytotoxicity cytotoxicity
NM-101
TiO2
NM-103
TiO2
NM-104
TiO2
NM-211
CeO2
NM-212
CeO2
NM-401
MWCNT
NM-402
MWCNT
NC 6200 = 1.0 52 800 = 1.0 a, c 15 800 = 1.0 21 800 = 1.0 a 25 700 = 1.0 a 43 200 = 1.0 b 26 100 = 1.0 a
10 1.8 * 0.9 0.8 0.9 a 0.9 1.7 a 0.8
100 cytotoxicity 0.9 2.3 * 1.8* 1.6 * 2.4 * 1.4 *
1000 cytotoxicity 1.5 * 2.3 a * cytotoxicity cytotoxicity cytotoxicity cytotoxicity
NM-103
TiO2
NC 4200 =1.0
10 1.0 a
100 1.1
1000 2.0 d *
NM-100
TiO2
NM-101
TiO2
NM-104
TiO2
NM-211
CeO2
NM-212
CeO2
NM-401
MWCNT
NC 14.0 = 1.0 14.0 = 1.0 14.0 = 1.0 14.0 = 1.0 23.1 = 1.0 b 19.1 = 1.0
10 1.8 * 2.3 a * 1.1 1.1 1.5 5.2 a *
100 2.6 * cytotoxicity 1.4 a 3.6 * 2.5 * 4.5
1000 cytotoxicity cytotoxicity 2.0 a * cytotoxicity cytotoxicity cytotoxicity
NM-100
TiO2
NM-101
TiO2
NM-104
TiO2
NM-200
SiO2
NM-211
CeO2
NM-212
CeO2
NC 200 = 1.0 b 500 = 1.0 4500 =1.0 b, c 2000 = 1.0 c 500 = 1.0 800 = 1.0 a
10 8.2 a * 3.0 * 0.6 1.3 a 1.7 a 1.0 a
100 12.9 * cytotoxicity 1.1 1.8 * 2.9 * 1.5 *
1000 cytotoxicity cytotoxicity 1.8 * 2.3 * cytotoxicity cytotoxicity
Table 7a - OECD reference NM causing significant IL-1α induction (x-fold of NC; NC: pg/mL) in
PCLuS at non-cytotoxic concentrations
Table 7b - OECD reference NM causing significant TNF-α induction (x-fold of NC; NC: pg/mL) in
PCLuS at non-cytotoxic concentrations
Table 7c - OECD reference NM causing significant CINC1 (IL-8) induction (x-fold of NC; NC: pg/mL) in
PCLuS at non-cytotoxic concentrations
Table 7d – OECD reference NM causing significant MCP-1 induction (x-fold of NC; NC: pg/mL) in
PCLuS at non-cytotoxic concentrations
Table 7e - OECD reference NM causing significant M-CSF induction (x-fold of NC; NC: pg/mL) in
PCLuS at non-cytotoxic concentrations
Table 7f - OECD reference NM causing significant OPN induction (x-fold of NC; NC: pg/mL) in PCLuS
at non-cytotoxic concentrations
• NC: negative control (DMEM/F-12)
• Cytokine assays:
NC— mean concentration of duplicate testing (pg/mL); set as 1.0
IL-1α determined in cell lysate
TNF-α, CINC1 (IL-8), MCP-1, M-CSF and OPN determined in PCLuS supernatant
Test substance effects— x-fold increase relative to the NC
• a: CV% N 20%; b: CV% N 50%
• c: NC did not meet respective acceptance criterion
• *Statistical signiﬁcance (p ≤ 0.05) in trend analysis
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Table 8
Overview of in vitro effects of 16 OECD reference nanomaterials in PCLuS (details: see
Footnote and Tables 3–7).
Tissue
Destruction
Cytotoxicity * Apoptosis Oxidative
Stress **
Inflammation** No Effect
TiO2, anatase NM-100 500 500 10
anatase NM-101 100 10 10
anatase NM-102 1000
rutile NM-103 1000
rutile NM-104 1000 100
rutile-
anatase NM-105 10 -1000
ZnO NM-110 10
NM-111 10
SiO2 NM-200 500 100
NM-203 10 -1000
CeO2 NM-211 1000 100
NM-212 1000 100
Ag NM-300K 50
MWCNT NM-400 10 -1000
NM-401 1000 500 10
NM-402 500 100
The lowest test substance concentrations (μg/mL) at which the respective effects were
observed are noted.
⁎ Signiﬁcant cytotoxicity at test substance concentrations not causing tissue destruction
⁎⁎ Signiﬁcant oxidative stress or inﬂammation at test substance concentration causing
neither tissue destruction nor cytotoxicity
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OPN) and both CeO2 NM-211 and NM-212 (both: TNF-α, CINC1 (IL-8),
M-CSF, and OPN) induced all three types of cytokines at non-cytotoxic
concentrations, i.e. the pro-inﬂammatory cytokines modulating
immune reactions, the chemokines inducing inﬁltration of inﬂammato-
ry cells into the lung tissue, and the cytokines inducing proliferation
of hematopoietic or sessile cells. TiO2 NM-100 only induced TNF-α, M-
CSF, and OPN, whereas TiO2 NM-103 induced CINC1 and MCP-1, there-
by being the only NM to induce MCP-1. SiO2 NM-200 induced IL-1α,
TNF-α, and OPN. MWCNT NM-401 induced CINC1 and M-CSF and
NM-402 TNF-α and CINC1 (Table 7a–f and SI Tables S6–S11).Test substance-speciﬁc observations taking into account histopathological
evaluations of the PCLuS test system
An overview of the in vitro effects induced by the 16 OECD reference
nanomaterials evaluated in the PCLuS test system is provided in Table 8.
In the following, these effects are compared to the outcome of the
histopathological evaluations.
The ion shedding nanomaterials, ZnO NM-110 and NM-111, and Ag
NM-300K, induced considerable tissue destruction, as evidenced by
severe loss of protein content in the BCA protein assay. Presumably,
the uncoated ZnO NM-110 was slightly more toxic than its coated
counterpart, since ZnO NM-111 did not induce signiﬁcant effects at all
test substance concentrations. Surprisingly in histopathology, ZnO
NM-111-exposed lung slices did not show any signs of cytotoxic effects,
but in the alveolar lumen in a non-concentration dependent manner.
Most likely, this observation is an artifact caused by technical problems.
In the histopathological evaluation of those lung slices exposed to Ag
NM-300K and the silver dispersant NM-300K DIS, condensed nuclei
and vacuolated cytoplasm of lung cells were observed, an indication of
autophagy, and possibly apoptosis, with more severe changes induced
by silver than its dispersant (Table 10 and Fig. 1).
Among the less- or insolublemetal oxide nanomaterials, pigmentary
(non-nano) anatase NM-100 and anatase NM-101 were the most toxic
TiO2 NMs evaluated in the present study, by inducing signiﬁcant
cytotoxicity combined with cytokine induction at non-cytotoxic
concentrations and, in the case of NM-100, caspase-3/-7 activation,and, in the case of NM-101, increased GSH concentrations. Both CeO2,
NM-211 and NM-212, showed similar levels of toxicity, inducing signif-
icant cytotoxicity and identical cytokine patterns, i.e. TNF-α, CINC1, M-
CSF, and OPN at non-cytotoxic concentrations. Histopathological
evaluation of the lung slices exposed to these test substances revealed
nanoparticles, seen as agglomerates of black, round particles, in
macrophages and free in the alveolar lumen, but no signs of cellular
death (Table 10 and Fig. 2a, presenting NM-102 agglomerates in the
alveolar lumen, and Fig. 2b, presenting NM-102 particles taken up into
macrophages).
SiO2 NM-200 signiﬁcantly activated caspase-3 and -7, however
without concurrent cytotoxicity. In histopathological evaluation of
NM-200-exposed PCLuS, single cell necrosis and eosinophilic material
in alveoli were observed, whereas the almost translucent SiO2 nanopar-
ticleswere hardly to be seenwith lightmicroscopy (Table 10 and Fig. 3).
Oxidative stress, as determined by increased GSH levels, but no cytotox-
icity, was observed for anatase TiO2 NM-102 (which induced none of
the cytokines) and for rutile TiO2 NM-104, which further induced all
three types of cytokines. Histopathological evaluation of PCLuS exposed
to these substances resembled those of the cytotoxic substances, how-
ever with slightly lower grades of severity at the higher concentrations.
Finally, TiO2 NM-103 only induced cytokines (i.e. CINC1 and MCP-1),
and TiO2 NM-105 and SiO2 NM-203 induced no signiﬁcant effects in
any of the assays.
The three different multi-walled carbon nanotubes included in the
present study differed considerably in the effects they elicited.Whereas
MWCNT NM-400 did not induce any signiﬁcant effects in any of the
assays, NM-401 and NM-402 caused signiﬁcant cytotoxicity, NM-401
also increased GSH levels and both NM-401 and NM-402 further
induced cytokines, i.e. CINC1 and M-CSF (in the case of NM-401) or
TNF-α and CINC1 (in the case of NM-402). In histopathology, none of
the MWCNT-treated PCLuS showed any sign of cell alteration, but
carbon nanotubes observable as ﬁbrous structures in the alveolar
macrophages and in the alveolar lumen (Table 10 and Fig. 4).
In comparison to the histopathological ﬁndings of the test substance-
treated lung slices, in PC(Triton X100)-treated PCLuS considerable cell
lysis had occurred resulting in a loss of cell nuclei and cellular structures
(Fig. 5). In the SiO2 NM-203 and CeO2 NM-212 test runs, however,
histopathological evaluation of the Triton X-100-treated lung slices did
not reveal any changes in cell morphology. These observations might
point to technical problems for these two test runs (Table 10). Finally,
histopathological evaluation of the NC, i.e. the PCLuS treated only with
cell culture medium (DMEM), revealed intact alveoli with no evidence
of foreign particles present either in the lumina or cells (Fig. 6).
Discussion
Inherent sensibility of the PCLuS test system
For in vitro or ex vivo test systems to become applicable for routine
regulatory testing, a test protocol has to be compiled that is sufﬁciently
straightforward to enable reliable test substance screening at a sufﬁ-
ciently high throughput. In the present study such a test protocol for
the PCLuS test system, using uniform 24-hour submerse test substance
exposure, has been evaluated. Furthermore, the same test substance
concentrations of 10 to 1000 μg/mL were consistently applied for all
assays, which were selected to cover relevant NM toxicity pathways,
i.e. cytotoxicity, apoptotic reactions, oxidative stress, and inﬂammatory
reactions. Standardization of test protocols, however, can prove very
challenging during in vitro test development (Fentem et al., 1995),
and the acceptance criteria and measures set up to verify test result
reliability and reproducibility reveal a number of limitations of the
PCLuS test system as it was used in the present study.
Test result reliability and reproducibility can be impaired by
limitations inherent to the tissue slice test system itself, arising both
from the preparation and the handling of the PCLuS. A crucial,
Table 9
Fulﬁllment of acceptance criteria (AC) and reproducibility of test results in the protein, WST-1, GSH, caspase-3/-7, and cytokine assays (numbers of NC and PC not meeting the AC and
numbers of measurements with CV% N20% and N50% as compared to reported mean intra- and interassay variabilities).
Assay NC-related
AC⁎⁎
No. of NC not
meeting AC
PC-related
AC⁎⁎
No. of PC not
meeting AC
Total no. of
measurements
(incl. NC & PC)⁎
No. of measurements
with CV% N20%
/of which N50%
Reported mean
intra-assay
variability (CV%)⁎⁎⁎
Reported mean
inter-assay
variability (CV%)
Mean NC Mean PC
Total protein ≥0.4 OD 0/17 ≤50 μg/mL 0/17 119 7/0 Not available Not available
WST-1 ≥0.5 OD 1/13 ≤10% relative to NC 0/13 91 5/1 b4.2 a Not available
Caspase-3/-7 ≤40% relative to PC 2/13 ≥60 000 RLU 3/13 91 13/0 Not available Not available
GSH ≥8000 RLU 5/13 ≤30% relative to NC 1/13 81 20/3 not available not available
IL-1α b1.0 ng/mL 4/12 No PC Not applicable 41 9/1 Not available
[6/12]
Not available
TNF-α b50 pg/mL 1/12 15/3 8.6 b [10] 13.5 b
CINC1 (IL-8) b40 ng/mL 2/12 10/3 b7.5 c [3/14] b6.5 c
MCP-1 b5 ng/mL 0/12 6/2 12.9 d [8/10] 8.1 d
M-CSF b30.0 pg/mL 2/12 10/4 b9 e [3/6] b9 e
OPN b1.5 ng/mL 4/12 11/10 b4 f [2] b6.6 f
NC: negative control (DMEM/F12); PC: positive control; AC: acceptance criterion; TR: test result; CV%: coefﬁcient of variation; RLU: relative luminescence unit
PC: WST-1 assay: 0.1% Triton X-100; caspase-3/-7 assay: 0.5 μM staurosporine; GSH assay: 10 mM DL-buthionine-[S,R]-sulfoximine (BSO); no PC in the cytokine assays.
In the protein, WST-1, and caspase-3/-7 assays, the total number of test substances equals 7 times (i.e. 5 test substance concentrations plus NC and PC) the number of test substances
included in the assay (i.e. 17 and 13 test substances). The total number of test results evaluated in the GSH assay equals the total number of test results evaluated in theWST-1minus 10
test substance concentrationswith signiﬁcant cytotoxicity in theWST-1 assay. In the cytokine assays, themaximumnumber of test resultswas 41, i.e. 12NM (TiO2 NM-105 also excluded),
no PC, only non-cytotoxic test substance concentrations, and only 3 test substance concentrations.
a: see Peskin and Winterbourn (2000)
b: Test kit leaﬂet for the ﬂow cytomix simplex Kit rat TNF-alpha (available at: http://www.bendermedsystems.org/bm_products/MAN/8622FF.pdf)
c: Test kit leaﬂet for the Quantikine rat CINC-1 ELISA (available at: http://www.rndsystems.com/Products/RCN100)
d: Test kit leaﬂet for the Flow cytomix simplex Kit rat MCP-1 (available at: http://www.bendermedsystems.org/bm_products/MAN/8631FF.pdf)
e: Test kit leaﬂet for the Quantikine Mouse M-CSF ELISA (available at: http://www.rndsystems.com/Products/MMC00)
f: Test kit leaﬂet for the Quantikine Mouse Osteopontin ELISA (available at: http://www.rndsystems.com/Products/MOST00)
⁎ Acceptance criteria (adapted from Lauenstein et al., 2012). Due to the strong cytotoxic effect of Triton X-100, in the WST-1 assay, the PC-related AC only conﬁrms that cell lysis has
occurred.
⁎⁎ Maximum number of test results
⁎⁎⁎ Figures in square brackets relate to own measurements in the PCLuS test system during standard curve determination (see Table S1)
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is the preparation of the tissues. The cutting of the slices is an insult that
can lead to cellular reactions, which might distort test results. Wohlsen
et al. (2003) address a number of potential tissue-related problems
when using PCLuS to measure small airway responses, such as cellular
changes induced by agarose instillation into the lung, pre-contraction
of the airways, and – in regard to the uniform quality of the tissue slices
– airways of different diameters being present in different slices. Assay-Table 10
Histopathological evaluation of PCLuS treated with OECD reference nanomaterials.
OECD reference No. and test substance Positive control Grade of severity
concentration [μ
10 1
NM-100 TiO2 P 2 4
NM-101 TiO2 P 1 2
NM-102 TiO2 P 1/1 1
NM-103 TiO2 P 1/1 1
NM-104 TiO2 P 1/2/1 2
NM-111 ZnO P 1 1
NM-200 SiO2 P 1 2
NM-203 SiO2 nad⁎⁎ nad n
NM-211 CeO2 P 1 2
NM-212 CeO2 nad⁎⁎ 1 1
NM-300K Ag
b 20 nm
P 1 2
NM-300KDIS Ag dispersant P nad 1
NM-401 MWCNT P 1/1 1
NM-402 MWCNT P 1/1 1
The numbers categorize the severity of the respective observation:
Grade 1: minimal; 2: slight, mild; 3: moderate; 4: marked, severe; 5: massive, extreme
P: histopathological ﬁndings present
NC: negative control (DMEM/F-12); PC: positive control (0.1% Triton X-100)
⁎ Tested at 840 μg/mL, i.e. the dispersed concentration calculated for NM-100
⁎⁎ nad = nothing adverse detected; histopathological evaluation points to technical problemspeciﬁc variations in the NCmeasurements indeed point to a certain de-
gree of tissue damage due to the cutting or handling of the lung slices
even though thesewere performedwith utmost care. They further indi-
cate that a certain degree of biological variability is to be expected in
PCLuS test systems. Recently, it has been suggested to delay exposing
PCLuS to test substances until 48 h after preparing the slices to reduce
responses caused by the slicing procedure itself (Behrsing et al., 2013).
Under the testing conditions of the present study, however, cell viabilityat respective
g/mL]
Observation
00 1000
4⁎ Particles in macrophages and free in alveolar lumen
4 Particles in macrophages and free in alveolar lumen
/2 1/3–4 Particles in macrophages and free in alveolar lumen
/2–3 1/3–4 Particles in macrophages and free in alveolar lumen
/2 2/4 Particles in macrophages and free in alveolar lumen
1/1–2 Particles in macrophages and free in alveolar lumen
3/2–3 Single cell necrosis and eosinophilic material in alveoli
ad 1/1 Particles in macrophages and free in alveolar lumen
–3 4 Particles in macrophages and free in alveolar lumen
/1 2/3 Particles in macrophages and free in alveolar lumen
/1–2 4/2 Condensed nuclei, vacuolated cytoplasm; particles in
macrophages and free in alveolar lumen
–2/1 4/1 Vacuolated cytoplasm; condensed nuclei; particles free
in alveolar lumen
/3 1/4 Particles in macrophages and free in alveolar lumen
/2–3 1/4 Particles in macrophages and free in alveolar lumen
s relating to test sample with positive control
Fig. 1. PCLuS treated with 1000 μg/mL Ag NM-300K: NMs inmacrophages and in alveolar
lumen; cells: condensed nuclei and vacuolated cytoplasm.
Fig. 2. a: PCLuS treated with 1000 μg/mL TiO2 NM-102: (Agglomerated) NMs in macro-
phages and in alveolar lumen. b: PCLuS treated with 1000 μg/mL TiO2 NM-103: (agglomer-
ated) NMs in alveolar lumen and additionally in macrophages.
Fig. 3. PCLuS treated with 1000 μg/mL SiO2 NM-200: Cell necrosis and eosinophilic mate-
rial in alveoli, translucent SiO2 NMs hardly to be seen.
Fig. 4. PCLuS treated with 1000 μg/mL MWCNT NM-401: NMs in macrophages and in
alveolar lumen.
Fig. 5. PCLuS treated with 0.1% Triton X-100: Considerable cell lysis resulting in a loss of
cell nuclei and cellular structures.
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Fig. 6. PCLuS treated only with cell culture medium (DMEM, i.e. negative controls): Intact
alveoli, no foreign particles to be detected.
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of the slices. Therefore the test substances were applied without recov-
ery period after the cutting procedure.
Whereas the uniform quality of monolayer cell culture test systems
can be established, e.g. by determining cell conﬂuence using light
microscopy, the quality of tissue slices can only be assessed indirectly.
Frequently, total protein content of the tissue slices – as a quantiﬁable
parameter relating to the cell numbers – is used to determine standard
quality and to rule out technical problems during to their preparation
(Henjakovic et al., 2008; Switalla et al., 2010a,b).
The BCA protein assay, applied in the present study to determine total
proteinmass, requires lysating the slices. Since only theWST-1 assay does
not in itself require lysating the slices, the BCA protein assay therefore
could only be performed upon completion of this assay, but not to verify
the quality of the slices used in the caspase-3/-7, GSH, or cytokine assays.
While all of the slices tested in the BCA protein assay were of acceptable
thickness, the range of total protein contents measured throughout the
entire study (i.e. between 159 μg/mL for the NC of TiO2 NM-105 and
422 μg/mL for the NC of ZnO NM-111) suggests that in the respective
test runs test substances at identical concentrationswere in fact applied
to differing numbers of cells. To address tissue variability (at least in the
WST-1 assay), the absorbance values calculated in this assaywere relat-
ed to the total protein contents of the tissue slices.Test result reproducibility and endpoint-speciﬁc observations
Coefﬁcients of variationexceeding20%wereobserved formean test re-
sults in all assays, however in different frequencies. A number of reasons
can be put forward for this: Inconsistencies in NM dispersion do not
seem to be the likely main cause since CV% values exceeding 20% were
also observed for the negative and positive controls. The BCA protein
and WST-1 assays were the most reproducible assays since they fulﬁlled
the respective NC- and PC-related AC and had overall satisfactory coefﬁ-
cients of variation. (It cannot be determined whether the higher CV%
values in the WST-1 assay recorded for TiO2 NM-103 at three different
test concentrations were caused by technical problems during test sub-
stance sampling, tissue slice preparation, or assay performance.)
In contrast, CV% values exceeding 20% were recorded frequently in
the GSH assay (23 of 81 measurements). GSH depletion is likely to be
a very sensitive endpoint that is already affected by the preparation of
the lung slices as revealed by the number of NCwith reduced GSH levels
(i.e. that did not meet the respective NC-related AC). Furthermore,in vitro glutathione levels have been reported to be very low to begin
with, making GSH difﬁcult to detect. Additionally, nanoparticles have
been observed to trigger the active export of intracellular glutathione
by increasing the activity of the ATP-dependent MRP/1 efﬂux pumps,
which in return leads to increased ROS production and cellular apopto-
sis (Seiffert et al., 2012; Stone et al., 2009). Increased GSH levels induced
by a number of NMs in the present study might be an indication of late
oxidative stress reactions that occur as a detoxifying defense mecha-
nism after the initial GSH decrease (Lin and Yang, 2007).
Consistent with the ﬁndings of the present study, also other in vitro
studies have highlighted IL-8 as an important cytokine to detect inﬂam-
matory reactions caused by different types of NMs (Donaldson et al.,
2008; Feltis et al., 2012; Hackenberg et al., 2011; Kermanizadeh et al.,
2013). Additionally, zinc nanoparticles of different shapes and sizes
have been observed to induce TNF-α (Roy et al., 2011) and MCP-1
(Gojova et al., 2007), and P-25 TiO2 NMs (21 nm) were found to induce
IL-1, IL-6, IL-8, and TNF-α in vitro (Park et al., 2008).
However, large variations of the PCLuS test results were observed for
the six different cytokine assays. Most likely, this was due to the different
affection of the lung cells during the cutting and handling procedure, as
conﬁrmed by high CV% values in the negative controls. For those
cytokines that were induced by a number of NMs (TNF-α, CINC1
(IL-8), M-CSF, and OPN), test result reproducibility was mediocre.
Cytokine inductions in PCLuS cannot be expected to be as pronounced
as immune reactions in vivo, since they are restricted to the piece of
tissue available in the ex vivo test systemand, e.g., attraction of immune
cells from the blood to the site of inﬂammation is not possible.
Therefore, cytokines are not considered to be core parameters in testing
NM toxicity in PCLuS.
As regards caspase-3/-7 activation, only two test substances (TiO2
NM-100 and SiO2 NM-200) elicited a statistically relevant effect. Never-
theless, the observation that the most pronounced effects in the
caspase-3/-7 assay frequently occurred at the second highest, or even
lower, test substance concentrations possibly point to the need to
further optimize the PCLuS apoptosis assay protocol. Wilhelmi et al.
(2012) cautioned against potential artifactswhen testing nanomaterials
in the caspase assay and ruled out possible false positive results by cell-
free testing of all materials. This measure is also recommended by the
supplier of the Caspase-Glo® 3/7 assay kit (http://www.promega.de/
~/media/Files/Resources/Protocols/ Technical%20Bulletins/101/Caspase-
Glo%203%207%20Assay%20Protocol.pdf).
Furthermore, in podocytes, 5 and 10 mg/mL human albumin, the
dispersing agent used in the present study, induced dose-dependent
caspase-3-/-7-activation and apoptosis (Okamura et al., 2013). There-
fore also albumin-addition to the culture medium might cause false
positive results. In contrast in the present study, apart from SiO2
NM-200, there was an overall lack of apoptotic effects.
Wilhelmi and co-authors found absorption measurements to be
wavelength-dependent in the caspase assay. They recorded ZnO and
TiO2 nanoparticles to be especially prone to decrease the luminescent
signal in the caspase-3/-7 assay and further reported high inter-
experimental variability of this assay. In the present study, unlike the
effect induced by TiO2 NM-100, the caspase-3 and -7 activation elicited
by SiO2 NM-200, did not correspond with cytotoxic cell death at the
tested concentrations. However singular cell necrosis and eosinophilic
material were observed in histopathology at the highest test con-
centrations. Caspase-3 activation without cell death has been reported
to occur in CD8+ T cells upon antigen presentation (McComb et al.,
2010). Likewise, cellular infections have been reported to induce
caspase-1 activating inﬂammasomes triggering the maturation of pro-
inﬂammatory cytokines to engage in innate immune defenses and
pyroptotic cell death (Lamkanﬁ, 2011; Schroder and Tschopp, 2010).
However, such immune reactions are very unlikely to have occurred
in the ex vivo lung slices. It remains to be determined whether longer
exposure times or longer post-exposure observations times would
have resulted in apoptotic cell death.
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the present study, was omitted after nanomaterial interferences with
the assay dye could not be prevented for all NMs as determined by
NM-reagent interferences in cell-free dispersions. Recently, however,
also an interference of P-25 TiO2 NM with the formazan dye used in
the MTT assay has been reported (Lupu and Popescu, 2013). For test
substance concentrations exceeding 50 μg/mL, this resulted in false
viability increases of up to 14%. Further investigations are required to
determine whether the cytotoxicity recorded for TiO2 NM-100 and
NM-101 in the present study has been inﬂuenced to some extent by
such NM-dye interactions. Recently however, Guadagnini et al. (2013)
have not found two different SiO2 NMs (15-30 and 25–50 nm, respec-
tively (TEM and DLS)), or TiO2 NM-105 (15–60 nm (TEM); 101 and
278 nm (bimodal size distribution in DMEM-F12-HAM culture medium;
DLS)) to interfere with the reagents of the WST-1 assay.
Limitations of the available positive controls
Positive controls serve tomonitor the inducibility of the PCLuS in the
respective assays. However, for the cytokine assays LPS was discarded
as positive control because of poor reproducibility of test results
resulting in frequent failure to meet the respective PC-related AC.
Feltis et al. (2012) also found the quality of LPS to be variable when
using it as a positive control to investigate ZnO NM effects on THP-1-
derived macrophage cultures. Additionally, as mentioned above, the
mode of action of LPS on inﬂammatory cells differs from that of NMs.
In the BCA protein and WST-1 assays (as well as in histopathological
evaluation), the effects caused by the PC Triton X-100 possibly were
too detrimental to calibrate mild or moderate effects caused by NMs.
This lack of suitable positive controls is an obstacle standing in the
way to the optimization of in vitro assays.
In regard to those assays where test results are recorded relative to
the NC or PC (i.e. caspase-3/-7 activation and GSH depletion/increase),
the difference between the effects measured for the NC and the PC
must be sufﬁciently high to allow for a meaningful assignment of
concentration-dependent test substance reactions. Overall in the
caspase-3/-7 assay, test substance-induced enzyme activation was not
considerably higher than caspase activation in the NC. Again, this
might point to a certain degree of pre-treatment tissue damage in the
lung slices. It might also point to the low apoptotic activity of the NMs
tested in relation to the much more pronounced effects of the positive
control staurosporine.
Test substance exposure duration and exposure type
In the caspase-3/-7 assay, the most pronounced effects oftentimes
were not recorded at the highest test substance concentration. Signiﬁcant
effects observed in the GSH assay only related to increased but not re-
duced GSH levels. Additionally, IL-1α, an important pro-inﬂammatory
marker, was hardly ever increased to signiﬁcant levels. All of these ﬁnd-
ings might be an indication that the early cellular effects investigated in
these assays might already have passed their peak at the time of
investigation.
As regards a timeline for the progression of apoptotic reactions
in in vitro cell culture test systems, Hussain et al. (2010) found
caspase-3/-7 activation upon exposure of 20 μg/cm2 TiO2 NM (12 nm,
TEM) to 16HBE14o- cells to reach a maximum after 2 h. After 30 min
of exposure, ROS production, lipid peroxidation, and lysosomal mem-
brane destabilization were induced, leading to cathepsin B release and
caspase-8 activation after 1 h, and caspase-3/-7 activation after 2 h
(Hussain et al., 2010). In RAW264.7macrophages, non-nano crystalline
silica DQ12 and amorphous SiO2 nanoparticles dose-dependently
(10–80 μg/cm2) induced caspase-3/-7 after 6-hour treatment, which
was signiﬁcant for DQ12 at 80 μg/cm2. After 24-hour treatment, how-
ever, increases in caspase-3/-7 activation were not signiﬁcant, andZnO nanoparticles were even found to reduce caspase activities below
those of untreated cells (Wilhelmi et al., 2012).
Different nanoparticle exposure times have also been selected to
detect different cytokines in vitro. Feltis et al. (2012) exposed human
THP-1 cell-derived macrophages to ZnO nanoparticles for 20 h before
conducting extensive cytokine analysis. Heng et al. (2011a) measured
TNF-α in primary murine dendritic cells after 6-hour exposure to ZnO
nanoparticles. Dufﬁn et al. (2007b) treated A549 cells to nanoparticle
carbon black and nanoparticle TiO2 for 4 h before measuring IL-8
in the culture supernatants. When applied to cultured human aortic
endothelial cells, ZnO nanoparticles increased ICAM-1 mRNA levels
after 1–2 h which then remained at an elevated level, whereas IL-8
andMCP-1mRNAexpression peaked at 2 h before decreasing to consid-
erably lower levels (Gojova et al., 2007).
Overall, the extent of endpoint-speciﬁc effect is dependent upon the
type of test system chosen. For instance, IL-8 concentrations induced
by TiO2 NM and diesel exhaust particles were lower in triple cell
co-cultures composed of humanA549 cells,macrophages, and dendritic
cells, than the expected values calculated from the respective monocul-
tures of each of the cell types (Müller et al., 2010). TNF-α concentra-
tions, on the other hand, were higher in the triple cell co-cultures,
revealing that the interplay of different lung cell types can substantially
modulate nanoparticle effects (Müller et al., 2010).
Exposure times found suitable for monolayer cell culture systems
are not per se also appropriate for tissue culture systems, since the test
substances are exposed to different cellular assemblages. For practical
reasons, a uniform exposure time for the different assays applied in the
PCLuS test system is desirable. As these speciﬁcations reveal, adaptations
of the test substance exposure times in the caspase-3/-7, GSH, and,
possibly, some of the cytokine assays might improve the validity of
these assays.
Finally, also the question whether application of the test sub-
stances dispersed in solution adequately reﬂects the situation
in vivo is a matter for further investigation. It has been suggested
that culturing PCLuS at an air-liquid interface might more closely re-
semble in vivo exposure (Herzog et al., 2013; Switalla et al., 2010b).
However, this technique is not yet well suited for high-throughput
screening assays.
Dose metrics and dosimetry
For adherent cell cultures, it has been recommended to relate nano-
particle mass to the culture dish surface area or to the number of cells
per unit surface area of the culture dish (Heng et al., 2011b; Rushton
et al., 2010; Stone et al., 2009). Due to the heterogeneous tissue structure
of the lung slices used as test system in the present study, the cell num-
bers per unit surface area of the culture dish are not uniform. Therefore,
in spite of the limitations of expressing NM concentrations in terms
of mass per unit volume (or mass per unit well surface area), this
dose metric was considered most suitable for the PCLuS test system.
In regard to the speciﬁc nanoparticle dispersion dynamics, calcula-
tions directly relating in vitro test substance concentrations to in vivo tar-
get tissue doses, i.e. lung burden, over a given exposure time are not
adequate for nanoparticles (Teeguarden et al., 2007). In contrast to solu-
ble chemicals, nanoparticles can settle, diffuse, and aggregate differently
according to their size, density, and surface physico-chemistry, and also
depending on the properties of the culture media applied. Gravitational
particle settling, diffusion, and agglomeration are processes that are ex-
pected to signiﬁcantly affect the cellular dose and hence the cellular effect
of the NMs (Hinderliter et al., 2010; Teeguarden et al., 2007). As a result,
slow or non-settling particles are more likely to evade common in vitro
measures of biological responses, such as cell death and protein expres-
sion as investigated within the time frame of typical in vitro experiments
(Teeguarden et al., 2007). Given their size, the regional deposition of NMs
in the respiratory tract in vivo ismainly governed by diffusion (Landsiedel
et al., 2012; Oberdörster, 2009).
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via ISDD model for the well-dispersed NMs (for which diffusion is
the predominant parameter) and directly via AUC for the strongly
agglomerated NMs (for which sedimentation is the predominant pa-
rameter), revealed vast differences in the effective dosages between
different NMs. They further indicated that the highest in vitro test
substance concentrations exceeded the highest in vivo dosage previ-
ously applied in rat short-term inhalation studies.
Whereas the broad dose range up to 1000 μg/mL was selected in
the present study to ensure eliciting the in vitro effects under inves-
tigation, thereby determining inducibility of the PCLuS test system,
further investigations are required to adequately adjust in vitro test
substance concentrations to the differing diffusion and sedimenta-
tion properties of different NMs and also to align in vitro dosages
to in vivo dosages.
Particle characteristics inﬂuencing particle effects
Physico-chemical properties of nanomaterials that have been recog-
nized to inﬂuence their inhalability, deposition efﬁciency, and toxicolo-
gy are their airborne and hydrodynamic size, size distribution, shape
(and aspect ratio), their state of agglomeration, surface properties and
functionalization (surface area, porosity, charge, reactivity, chemistry/
coatings, contaminants), as well as solubility and crystallinity (Kuempel
et al., 2012; Nel et al., 2013a; Oberdörster, 2009; Oberdörster et al.,
1994; Rodriguez-Yanez et al., 2013; Zhu et al., 2013). Also in in vitro
cytotoxicity assays, particle size, surface chemistry and coating, as well
as chemical composition have been recognized as key determinants of
nanoparticle adverse effects (Feltis et al., 2012; Horev-Azaria et al.,
2011; Kroll et al., 2011). For nanotubes and ﬁbers, the number concentra-
tion of speciﬁc sized structures has been associated with inﬂammatory
effects (Donaldson et al., 2010). Furthermore, at equivalent cytotoxic
loads, smaller nanoparticles induced greater cellular immune responses
(Feltis et al., 2012).
As regards chemical properties of the NM test substances applied
in the present study, the ion shedding ZnO and Ag NMs induced the
strongest toxic effects in the PCLuS test system. Regarding those NMs
inducing moderate cytotoxicity, anatase TiO2 NMs elicited stronger
effects than rutile or rutile-anatase NMs of the same chemical composi-
tion, since two of the anatase TiO2 NM (NM-100 and NM-101) caused
cytotoxicity (with corresponding caspase-3/-7 activation or GSH
increase) and the third one oxidative stress (NM-102), which was
also recorded for rutile NM-104, whereas rutile-anatase NM-105
did not cause any adverse effects in any of the assays performed
(no cytokine assays were performed for NM-105) and rutile NM-103
only inﬂammation. Other in vitro studies have also recorded higher
cytotoxic potency for anatase TiO2 NMs than for the rutile form
(Johnston et al., 2009).
The hydrophobicity and hydrophilicity of NMs and the amount of
phospholipids present on the NM surface are further important factors
determining NM cellular uptake and intracellular distribution
(Landsiedel et al., 2012; Zhu et al., 2013). Hydrophobic nanoparticles
are generally poorly dispersed in biological ﬂuids and culture medium.
They tend to form aggregates or interact with hydrophobic residues of
blood proteins or peptides to enhance their dispersion. Likewise, NMs
taken up as aggregates or agglomerates tend to be less avidly cleared by
the host, and residual nanoparticles in macrophages or stromal cells
could last several months, thus possibly leading to cumulative toxicity
(Zhu et al., 2013).
In the present study, bovine serum albumin-containing cell culture
medium together with ultrasonication proved very effective in de-
agglomerating carbon nanotubes, but also considerably reduced ag-
glomeration for metal oxide nanomaterials (with very few exceptions;
as compared to a phospholipid-containing dispersing agent; data not
shown). Hydrophobic materials had a stronger tendency to agglomer-
ate and a higher BSA afﬁnity than the hydrophilic variants of the sameinorganic core thereby minimizing the total interfacial energy of the
suspension.
Comparison of NM effects in the PCLuS test system to in vivo observations
To the best of the authors' knowledge, the present study is theﬁrst ex-
tensive evaluation of the applicability of the PCLuS test system for NM
toxicity testing. Whereas all selected endpoints could be elicited,
reﬂecting the spectrum of early cellular effects caused by NMs, the test
protocol applied can only be considered preliminary, and the effects
observed should not be regarded quantitative. Nevertheless, in the
following, the results obtained with the PCLuS test system are compared
to mechanisms of action recorded for the respective chemical types of
NMs and to the results from in vivo rat inhalation toxcity studies
published in the literature. Thereby, a ﬁrst indication of the predictivity
of the PCLuS test system is obtained. Since, however, the results from a
rat PCLuS test system are only compared to data obtained in in vivo rat
studies, extrapolations to possible effects in humans do not form part of
this comparison.
Ion-shedding NMs that caused tissue destruction. The detrimental
effects of ZnO nanoparticles on in vitro tissue integrity observed in the
study at hand are well established. Mechanisms of action addressed for
ZnONMs are dissolution and release of heavymetal ions capable of ROS
generation, inﬂammatory reactions inducing IL-8, IL-6, and TNF-α
production, lysosomal damage, and cytotoxicity (Damoiseaux et al.,
2011; Meng et al., 2009; Nel et al., 2009, 2013a). In vitro, dissolved
Zn2+ ions have been reported to enter the mitochondria where they
cause mitochondrial dysfunction, caspase activation, and cell apoptosis
(Kao et al., 2012).
Also in vivo, ZnO NM effects are reported being caused by dissolved
ions (Kuempel et al., 2012), as recorded by increased LDH levels in the
bronchoalveolar ﬂuid (BALF; Kao et al., 2012). Klein et al. (2012) found
short-term inhalation exposure to 2.5 and 12.5 mg/m3 Z-COTE® HP1 to
increase inﬂammatory parameters in the BALF in a concentration-
dependent manner. In pulmonary histology, reversible granulocyte
inﬁltration and increases in alveolar macrophages were observed (Klein
et al., 2012).
Mechanisms of action recognized for silver nanoparticles are
dissolution and Ag + release inhibiting respiratory enzymes and
ATP production, and causing ROS generation, as well as disruption
of membrane integrity and transport processes (Damoiseaux et al.,
2011; Meng et al., 2009; Nel et al., 2009, 2013a). Accordingly, the tis-
sue destruction observed for Ag NM-300K in the present study was
most likely caused by release of silver ions into the solution
(Johnston et al., 2010).
In vivo studies determining Ag NM effects upon inhalation are scarce
in the literature. After in vivo 4-hour whole body chamber inhalation
exposure to 18–20 nm silver NM (76–750 μg/m3; corresponding
to 0.94–3.08 × 106 particles/cm3), rats did not develop any adverse
pulmonary effects within the 2-week observation period (Sung et al.,
2011). However, Sung and co-authors do not report performing any
histopathological evaluations that would allow comparing effects
induced in vivo on the cellular level to in vitro cytotoxic events. Upon
subchronic inhalation exposure (49–515 μg/m3; corresponding to 0.6–
3.0 × 106 particles/cm3) to 15 or 18 nm Ag NMs, chronic alveolar
inﬂammation and small granulomatous pulmonary lesions were
observed (Sung et al., 2009) that did not regress in male, but in female
rats (Song et al., 2013).
As discussed above, the highest concentrations applied in the PCLuS
studies exceed the highest in vivo dosages. However, since tissue
destruction was already recorded at concentrations of 10 and 50 μg/mL,
the pronounced in vitro cytotoxicity of both ZnO andAgNMs presumably
reﬂect inﬂammatory effects in vivo that can be observed by cytological
and histopathological evaluations. Chronic effects or reversibility of NM
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mirrored in the PCLuS test system.
Metal oxide nanomaterials reported to be of moderate cytotoxicity. Mech-
anisms of action recognized for TiO2 nanomaterials are glutathione
depletion and toxic oxidative stress as a result of photoactivity and
redox properties, protein ﬁbrillation and cell membrane disruption
Ieading to cell death (Damoiseaux et al., 2011; Meng et al., 2009; Nel
et al., 2009, 2013a). In the present study, anatase NM-100 and NM-
101 caused signiﬁcant cytotoxicity at 500 and 1000 μg/mL (NM-101
additionally at 100 μg/mL). Three of the 4 NMs causing signiﬁcant
oxidative stress at non-cytotoxic concentrations were TiO2 NMs, i.e.
anatase NM-101 and NM-102 and rutile NM-104. Furthermore, NM-
100 increased caspase-3/-7 activities at its cytotoxic concentrations. In
the cytokine assays, CINC1 (IL-8) and M-CSF were induced by anatase
and rutile TiO2 NMs, whereas TNF-α was only induced by anatase
TiO2 NM-100.
In vivo adverse effects of TiO2 NMs have been reported to be lung
inﬂammation and, upon long-term exposure, pulmonary ﬁbrosis, related
to the total deposited or retained particle dose in the target respiratory
tract region. For TiO2 NMs, dose metrics related to adverse effects are
surface area, volume, mass or number (by particle size fraction), with
the dose–response relationship possibly being non-linear at low doses
(Kuempel et al., 2012). In a rat short-term inhalation study (STIS; 5-day
exposure period, 6-hour exposure/day), both nanoscaled (70% anatase/
30% rutile, 20–30 nm, TEM; test substance concentration 100 mg/m3)
and pigmentary (non-nano) TiO2 (200 nm, DLS; test substance concen-
tration 250 mg/m3) induced reversible mild neutrophilic inﬂammation
and activation of macrophages in the lung (van Ravenzwaay et al.,
2009). After exposing rats to 10 and 50 mg/m3 TiO2 NMs (25 nm, TEM)
in the STIS, MCP-1, M-CSF, and OPN were signiﬁcantly increased in a
dose-dependent manner immediately after the ﬁnal exposure. For the
10 mg/m3, but not the 50 mg/m3, dose group, these effects returned to
control levels after a recovery period of 16 days (Ma-Hock et al., 2009a).
Again, the PCLuS test system can only be expected to reﬂect early
in vivo effects discernible on the cellular level, but neither progressive
chronic reactions, nor the reversibility of effects.
Cytotoxic mechanisms reported for CeO2 nanomaterials are
inﬂammasome activation and protein aggregation and ﬁbrillation (Nel
et al., 2009, 2013a). In the PCLuS test system, the tested CeO2 NMs were
observed to be of moderate cytotoxicity. In vivo, cerium dioxide NMs
have been reported to cause inﬂammatory reactions: In an acute
inhalation study with rats, 15–30 nm CeO2 nanoparticles (641 mg/m3)
increased inﬂammatory parameters in the BALF, including IL-1β, TNF-α,
and IL-6 induction, and multifocal pulmonary microgranulomas were
observed 14 days post exposure (Srinivas et al., 2011). In a STIS (Klein
et al., 2012; Landsiedel et al., 2010), 0.8, 3.2, and 11.4 mg/m3 CeO2 NMs
affected all cytological and biochemical parameters of the BALF in rats
and induced IL-1α, CINC1, MCP-1, and M-CSF in BALF and lung tissue
(in comparison: both CeO2 NMs used in the present study induced TNF-
α, CINC, M-CSF, and OPN). In vivo histopathology revealed diffuse
histocytosis. Compared to TiO2, CeO2 exerted higher local irritation
potential, and the effects were only partially reversible within the
3-week or 2-month observation periods (Klein et al., 2012). Evidently,
the PCLuS test system used in the present study, is unable to reﬂect
such a complex interplay of in vivo effects.
Mechanisms of action causing cytotoxicity reported for SiO2
nanomaterials are ROS production, pro-inﬂammatory stimulation,
protein unfolding, and membrane disruption (Damoiseaux et al., 2011;
Meng et al., 2009; Napierska et al., 2010; Nel et al., 2009, 2013a). The
observations made for SiO2 NMs in the present study do not provide a
uniform picture of such in vitro effects: Whereas SiO2 NM-203 was one
of the few test substances not to elicit any signiﬁcant response in any of
the assays, SiO2 NM-200 activated caspase-3 and -7, which was reﬂected
in histopathological evaluation (single cell necrosis and eosinophilic
material), but did not coincide with cytotoxicity in the WST-1 assay.In vivo short-term and subchronic inhalation studieswith amorphous
SiO2 nanoparticles demonstrated largely reversible lung inﬂammation,
granuloma formation, and focal emphysema without progressive lung
ﬁbrosis, as reviewed by Napierska et al. (2010) and Klein et al. (2012).
In the rat STIS, neither precipitated SiO2 NM-200 nor NM-203 induced
any changes in the BALF or lung tissue between test substance concentra-
tions of 0.5–10 mg/m3 (Klein et al., 2012). In consequence, further inves-
tigations are necessary to substantiate the test results obtained for the
SiO2NMs in thepresent study and to establish in vitro-in vivo correlations
for SiO2 nanomaterial effects.
Effects produced by the multi-walled carbon nanotubes. Mechanisms
of action reported for MWCNT are ‘frustrated phagocytosis’ (i.e. stiff,
non-degradable MWCNT overwhelming the phagocytic capacity of
tissue macrophages thereby causing chronic tissue inﬂammation) and
DNA oxidative injury, generation of ROS due to the metal impurities
trapped inside the carbon nanotubes, pro-inﬂammatory effects due
to oxidant injury, and pro-ﬁbrogenic responses, and the intensitiy
of these effects is reported to change with differing ﬁber sizes
(Damoiseaux et al., 2011; Meng et al., 2009; Nel et al., 2009, 2013a,b;
Rodriguez-Yanez et al., 2013).
The effects elicited byMWCNT in the present study do not provide a
consistent picture of their in vitro cellular effects. MWCNT NM-400was
one of the few test substances not to elicit any signiﬁcant effects in any
of the assays. The other two MWCNT (NM-401 and NM-402) caused
cytotoxicity at 1000 μg/mL and inﬂammatory reactions at non-cytotoxic
concentrations (with both substances inducing CINC1 (IL-8), and NM-
401 additionally inducing M-CSF, and NM-402 additionally TNF-α). Fur-
thermore NM-401 increased GSH levels. Hence, the only pro-ﬁbrogenic
cytokine to be induced under the applied test conditions was M-CSF by
MWCNT NM-401.
In vivo, MWCNTs have been observed to induce inﬂammatory
reactions both upon acute and subchronic exposure: Rats exposed to
0.1, 0.5, or 2.5 mg/m3 MWCNT Nanocyl® NC 7000 (equivalent to NM-
400) by inhalation for 90 days developed concentration-dependent
inﬂammatory reactions in BALF and histopathology (Ma-Hock et al.,
2009b). Also in a rat STIS, 2, 8, and 32 mg/m3 MWCNT NM-400 and
MWCNT NM-402 incuded inﬂammatory changes in the BALF (Klein
et al., 2012). In a further rat STIS investigating 0.5 and 10 mg/m3
MWCNTs (primary structure of 15 nmouter diameter ﬁbers, andﬁbrille
formation at the intermediate structural range between 100 nm and
1 μm), inﬂammatory changes in the BALF were also observed (Ma-
Hock et al., 2013). Additional investigations are necessary to speciﬁcally
relate the observations made for the different MWCNTs in the PCLuS
test system to speciﬁc in vivo effects.
Conclusion
With up to 120 slices to be prepared from a single rat lung, in vitro
test systems making use of precision-cut lung slices could considerably
reduce the numbers of animals required to detect pulmonary effects of
nanomaterials as compared to in vivo studies. However, the PCLuS test
protocol designed for routine testing of nanomaterials in the present
study, determining cytotoxicity, caspase-3/-7 activation, glutathione
reduction/increase, and cytokine induction after uniform 24-hour
exposure, requires further optimization before it could come into
consideration for pre-validation to assess its relevance and reliability
for regulatory testing. In comparison to simple monocell culture assays,
or a battery of such assays, proof-of-evidence could not yet be provided
that the PCLuS possess an added value in detecting nanomaterial
pulmonary toxicity.
Overall, the PCLuS test system seems susceptible to interferences
with different steps of the test protocol, as observed by high variability
of test substance measurements between biological replicates, high
variations in the negative control measurements, and generally high
negative controls (especially in the cytokine assays). The unavailability
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an efﬁcient development of the in vitro test protocols. The uniform
24-hour exposure duration prior to investigating the broad spectrum
of endpoints, desirable for application of the test system for routine
testing, presumably is not adequate for the caspase-3/-7, GSH, and cyto-
kine assays. Also the option to delay test substance exposure after prep-
aration of the tissue slices in order to better distinguish preparation-
induced effects from test substance effects, should be investigated. In
consequence, the results obtained in these assays should be considered
preliminary.
Themost robust endpoints investigated under the testing conditions
of the present study assessing the effects of nanomaterials were the BCA
protein and WST-1 cytotoxicity assays. These assays revealed tissue-
damaging effects of the ionizing nanomaterials (ZnO and Ag) and
cytotoxicity for two anatase TiO2 NMs, both CeO2 NMs, and one
MWCNT. For the caspase-3/-7, GSH, or cytokine assays, the obtained
results could not be consistently correlated to effects observed in
in vivo studies. However, also other in vitro studies, making use of cell
culture systems, do not yet provide consistent results allowing reliably
predicting NM in vivo effects.
In summary, the present study conﬁrms that PCLuS are able to detect
different early effects of NM toxicity. Nevertheless, investigation of
these effects cannot be considered sufﬁcient to predict the much more
complex and intricate apical effects that NMs might potentially induce
in vivo. Furthermore, since the lung tissue burdens in the PCLuS were
about three orders of magnitude higher as compared to those obtained
in the STIS, any effects seen in PCLuS may not have occured in the
in vivo studies. Further work is required to adjust in vitro test substance
concentrations to the differing diffusion and sedimentation properties of
different NMs. This is a prerequisite to ensuring that the results from dif-
ferent nanoform test substances obtained in different in vitro studies are
comparable. Most importantly, it is a prerequisite to ensuring that the re-
sults obtained in in vitro studies can be compared to NM effects in vivo.
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